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“La scienza deve abbandonare il terreno 
dell'incontrollata genialità individuale, del 
caso, dell'arbitrario, della sintesi affrettata e 
procedere sulla base di uno sperimentalismo 
fondato sulla consapevolezza della natura 
strumentale delle facoltà conoscitive…la 
conquista di verità nuove non può essere 
opera del singolo, ma solo di una collettività di 
scienziati organizzata a questo scopo”. 
            Francis Bacon  
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1. Riassunto  
 
 Nella sequenza delle proteine del latte sono criptati peptidi cosiddetti ‘bioattivi’, 
di lunghezza variabile tra 3 e 20 residui amminoacidici, rilasciati per digestione 
enzimatica in vivo od in vitro. 
È stato dimostrato che, a seconda della sequenza amminoacidica, essi 
possono esplicare attività specifiche in diverse classi di prodotti naturali o sintetici del 
tipo antitrombotico, antiipertensivo, oppioide, immunomodulante ed antimicrobico (1). 
 Oggetto della tesi di dottorato è la preparazione, a livello di laboratorio ed a 
livello di impianto pilota, di una classe di peptidi bioattivi, suscettibili di utilizzazione 
industriale come ingrediente nutraceutico. Nutraceutico è un termine, derivante dalla 
unione di “nutrizione" e "farmaceutico", col quale si designano alimenti o nutrienti 
estratti dagli alimenti che svolgono sia azione di prevenzione di patologie sia azione 
benefica sulla salute umana. Questa categoria di peptidi bioattivi comprende i 
fosfopeptidi della caseina bovina.  
 I fosfopeptidi (CaseinoPhosphoPeptides, CPP) sono rilasciati dalla caseina, a 
seguito di idrolisi enzimatica delle frazioni caseiniche κ-, αs1-, αs2-, e β-CN (2). Essi 
sono caratterizzati da una sequenza consenso del tipo SerP-X-SerP/ThrP/Glu/Asp, 
dove X è un qualsiasi residuo amminoacidico eccetto Pro e non contengono residui 
di tirosina e di istidina fosforilati. Una sequenza comune alle frazioni αs1-, αs2-, e β-
CN è -Ser(P)-Ser(P)-Ser(P)-Glu-Glu- (3). I CPP sono interessanti perché 
sopravvivono al passaggio gastrointestinale (4) e si ritrovano nello stomaco, nel 
duodeno e nell’ileo distale dopo ingestione di latte (5). Fungono da trasportatori di 
cationi minerali di- o trivalenti, aumentandone la biodisponibilità per l’assorbimento 
nel piccolo intestino (6). É stato, infatti, dimostrato che i CPP, in particolare i peptidi 
(1-25)4P della β-caseina e (59-79)5P dell’αs1-caseina, aumentano l’uptake di calcio 
in cellule tumorali umane differenziate in senso enterocitico (HT-29) (7), nelle cellule 
Caco2 (8), e negli osteoblasti (9). Questi dati ci hanno suggerito la possibilità di 
utilizzare i CPP come vettori di Ca2+ in alimenti funzionali per aumentarne la 
biodisponibilità nello sviluppo dell’organismo, nella calcificazione delle ossa e nella 
prevenzione dell’osteoporosi.  
 E’ stato poi dimostrato che i CPP sono capaci di stabilizzare le soluzioni di 
fosfato di calcio amorfo (ACP), formando piccoli cluster del tipo CPP-ACP, fino ad 
una taglia-limite, oltrepassata la quale il fosfato di calcio comincia a precipitare con 
formazione di nuclei cristallini (10). Il meccanismo di azione sarebbe il seguente: i 
CPP trasportano l’ACP sulla superficie del dente, inibendo la demineralizzazione 
dello smalto dentale e promuovono la rimineralizzazione delle lesioni superficiali (11). 
Essi svolgono anche un ruolo indiretto nel contrasto alla carie, impedendo l’adesione 
alla superficie del dente di Streptococcus mutans o di altri streptococci (12). 
 Il complesso CPP-ACP, ideato da Eric Reynolds dell’Università di Melbourne, 
è commercializzato come prodotto per la cura orale (RecaldentTM) e viene aggiunto 
come ingrediente nutraceutico in gomma masticante (Trident White Gum), paste 
dentifricie (GC Tooth Mousse) ed in altri prodotti.  
Esistendo sul mercato preparazioni commerciali di CPP (Arla, Danimarca,  
Tatua, Nuova Zelanda), è stata fatta un’indagine conoscitiva tesa a stabilirne la 
composizione in CPP. L’analisi mediante MALDI ha rivelato che i due prodotti 
commerciale sono costituiti in effetti da una miscela di CPP e di peptidi non 
fosforilati. Non essendo conosciuto il sistema di preparazione di questi prodotti, è 
probabile che l’innovazione operata da queste industrie a livello di prodotto sia stata 
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l’utilizzazione di uno o più enzimi in sequenza per generare CPP. Le preparazioni 
commerciali contengono infatti peptidi a diversa taglia molecolare cosa che indica 
una procedura differente di preparazione. Non esistendo sul mercato un 
preparazione di CPP esente da peptidi non fosforilati, l’obiettivo della tesi è stato 
quello di elaborare un procedimento per ottenere CPP ad elevata concentrazione, 
cioè peptidi a diverso grado di fosforilazione, presenti nella caseina nativa, esenti da 
peptidi non fosforilati.  
 La prima parte del lavoro è stata, quindi, focalizzata sull’individuazione di una 
metodologia di frazionamento degli idrolizzati enzimatici di caseina per il 
raggiungimento dell’obiettivo prefissato. Sono stati considerati diversi procedimenti di 
arricchimento dei CPP: a) precipitazione come sali di bario insolubili (13); b) 
derivatizzazione chimica (14); c) cromatografia di affinità su c1) ioni metallici 
immobilizzati (IMAC) (15); c2) su ossidi di metallo (MOC) (16).  
 La derivatizzazione chimica dà basse rese di prodotto ed un prodotto finale più 
complesso di quello iniziale (17). Le tecniche cromatografiche IMAC e MOC 
consentono di arricchire la preparazione in CPP, ma recuperano anche peptidi non 
fosforilati di natura acida (18). L’accoppiamento di resine con ossidi di metallo 
modificati da idrossiacidi alifatici (19), l’impiego di tamponi di caricamento su TiO2 
contenenti acido 2,5-p-idrossibenzoico (DHB) (18), la precipitazione con fosfato di 
calcio accoppiato all’arricchimento IMAC (20), la combinazione di cromatografia a 
scambio cationico (SCX) e scambio anionico (SAX) (21) si sono dimostrati capaci di 
arricchire, su base analitica, le preparazioni di CPP, ma non sono scalabili allo stato 
industriale. Tuttavia, nessuno dei sistemi analitici sperimentati potrebbe trovare 
applicazione alimentare, sostanzialmente per tre ragioni: a) la matrice a cui sono 
legati i CPP non è edibile; b) l’eluizione di CPP dalla matrice richiede sistemi di 
purificazione molto lunghi e costosi; c) l’aggiunta all’alimento dei CPP eluiti altera il 
gusto conferente una marcata nota di amarognolo, anche per la capacità dei CPP di 
chelare gli ioni minerali con cui viene a contatto. 
 La seconda parte del lavoro è stata rivolta alla messa a punto di una tecnica di 
arricchimento specifica per fosfoproteine e peptidi fosforilati, allo scopo di disporre di 
un procedimento preparativo di CPP da utilizzare successivamente come ingrediente 
in alimenti funzionali. L’idea è stata quella di sviluppare una tecnica analitica da 
adattare successivamente a fini preparativi. Essa prevede l’impiego come matrice 
cromatografica dell’idrossiapatite (HA), una forma cristallina di fosfato di calcio 
[Ca10(PO4)6(OH)2], rinvenibile nel tessuto osseo e dentale, largamente impiegata in 
medicina per protesi ortopediche e dentali, per favorire la completa integrazione del 
metallo nel tessuto osseo umano. Il meccanismo di funzionamento dell’HA prevede 
che i gruppi carichi negativamente delle proteine (gruppi carbossilici e fosfato) 
interagiscano con gli ioni Ca2+ (C-sites) del reticolo cristallino formando legami di tipo 
elettrostatico (22). Le proteine fosforilate vengono in tal modo immobilizzate sulla 
resina, mentre quelle non fosforilate vengono allontanate mediante lavaggio con 
tamponi di opportuna composizione. L’affinità delle frazioni caseiniche per 
l’adsorbente è tanto maggiore quanto maggiore è il grado di fosforilazione della 
proteina (22). Abbiamo dimostrato che l’affinità dei CPP nei riguardi dell’HA è simile 
a quello esibita dalle fosfoproteine. In dettaglio, si è trovato che l’HA lega i 
fosfopeptidi presenti, in quantità anche sub-stechiometrica, in miscele complesse di 
peptidi. Se si dispone di fosfoproteine genitrici legate all’HA, si possono generare in 
situ, a mezzo di un’opportuna idrolisi enzimatica, i corrispondenti fosfopeptidi. I CPP 
rimangono legati alla resina, mentre tutti quelli non fosforilati, ad esempio αs1-CN 
(f91-100) (m/z 1266.7) e αs1-CN (f8-22) (m/z 1758.9), presi come esempi di peptidi 
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acidi non fosforilati, vengono allontanati con i tamponi di lavaggio. Per sviluppare il 
corrispondente procedimento industriale è stato ideato un metodo a livello di 
laboratorio. Si produce un’idrolisi triptica della caseina fresca legata all’HA. I CPP 
rimangono legati all’HA, mentre i peptidi non fosforilati vengono allontanati con 
lavaggi, fino ad ottenere un prodotto lavato con acqua distillata. Il prodotto viene, poi, 
essiccato per la conservazione della polvere per tempi dell’ordine di anni a 
temperatura ambiente.  
È stato, poi, affrontato il problema di stabilire quali peptidi rimangano legati 
alla resina. Per questo è stato elaborato un sistema di controllo di qualità della 
preparazione, utilizzando tecniche di spettrometria di massa quali MALDI-TOF, LC-
ESI/MS e LC-ESI-MS/MS. Abbiamo dimostrato che ognuna di queste tecniche 
consente di caratterizzare i CPP legati alla resina. Dallo studio è risultato che la 
resina immobilizza una pletora di peptidi, tra cui i CPP con fosforilazione multipla del 
tipo αs1-CN (f59-79)5P (2720.91 Da), β-CN (f1-25)4P (3122.26 Da) e αs2-CN (f46-
70)5P (3087.99 Da), ognuno caratterizzato dalla sequenza cluster (Ser(P)-Ser(P)-
Ser(P)-Glu-Glu), funzionale al trasporto di ioni metallici.  
 La preparazione del complesso HA-CPP, in scala semi-industriale, ha 
suggerito di sintetizzare l’HA, a causa degli elevati costi di questo materiale, invece 
che utilizzare il costoso prodotto commerciale. Pertanto, l’HA è stata sintetizzata per 
via umida a partire da Ca(OH)2 e H3PO4, utilizzando condizioni di temperatura e pH 
ottimali, per l’ottenimento di cristalli di apatite pura. La capacità legante della resina 
sintetizzata è stata valutata confrontando la capacità legante dei CPP in 3 diverse 
miscele proteiche: caseina isoelettrica, proteine del latte (caseine + sieroproteine non 
fosforilate) e latte. L’analisi MALDI-TOF ha evidenziato la cattura, da parte dell’HA 
sintetica, degli stessi CPP, in quantità simili, nonostante la diversa complessità della 
matrice di partenza. La prova ha, quindi, dimostrato che il procedimento è scalabile 
per fini industriali. Una volta ottenuto il complesso HA-CPP su scala pilota, si è 
passati alla progettazione di un alimento funzionale. È stato scelto come alimento 
funzionale il latte poiché l’aggiunta al latte di quantità variabili tra 2.0 e 5.0g del 
complesso CPP-ACP⁄litro aumenta la capacità dei CPP a ripristinare la 
mineralizzazione delle lesioni dello smalto dentale (23), facendo aumentare 
rispettivamente dell’ 81% e del 164% il contenuto in minerali (calcio e fosfato) del 
latte “nativo” (24). Naturalmente, data la maggiore densità, i granuli di HA-CPP, 
prima dell’aggiunta al latte, sono stati finemente triturati per evitare l’immediata 
sedimentazione nel latte. Tuttavia, prima del consumo, la bevanda deve essere 
agitata, per rendere omogenea la sospensione. Una volta agitata, la bevanda 
arricchita di CPP ha mostrato le stesse caratteristiche sensoriali del latte di partenza, 
in quanto i gruppi fosfato dei CPP sono neutralizzati dagli ioni calcio dei cristalli di 
HA. Il complesso HA-CPP è inodore ed insapore. Nelle prove di recupero dei granuli 
di HA aggiunti al latte mediante centrifugazione, l’analisi MALDI dei granuli ha 
mostrato che l’HA è capace di legare i CPP liberi e la caseina solubile del latte. In 
altre prove, i granuli di HA-CPP aggiunti al latte si sono rivelati capaci di mantenere 
legati i CPP della preparazione e di chelare anche i CPP liberi del latte. 
 Per stabilire la quantità di CPP aggiunta nel latte, è stato affrontato il problema 
di un dosaggio quantitativo applicabile ad una qualsiasi matrice alimentare. Sono 
stati scelti come modello per la valutazione quantitativa i CPP del tipo 
monofosforilato, αs1-CN (f106-119)1P con sequenza VPQLEIVPNpSAEER, e 
difosforilato, αs1-CN (f43-58)2P con sequenza DIGpSEpSTEDQAMEDIK. Il metodo 
quantitativo si basa sull’utilizzo di standard interni a base di fosfopeptidi sintetici 
analoghi a quelli naturali. E’ stato verificato che il peptide naturale e quello analogo 
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sintetico, modificato in un solo sito amminoacidico, ionizzano allo stesso modo. I 
peptidi sintetici utilizzati si sono rivelati, dunque, idonei a fungere da standard interno 
per l’analisi quantitativa dei CPP monofosforilati e difosforilati. La misura delle aree 
sottese dalle coppie di picchi MALDI/MS dei peptidi monoP e diP ha consentito di 
costruire delle rette di calibrazione. Utilizzando tale sistema analitico si è potuto 
stabilire sia la quantità di CPP presente nel complesso HA-CPP, sia quella aggiunta 
nel latte da rendere funzionale. 
 Nella terza parte del lavoro di tesi, è stato affrontato il problema della 
valutazione della qualità della preparazione sperimentale a base di CPP. Com’è 
noto, la presenza di proteasi attive nel latte, a seguito di stati patologici della 
ghiandola mammaria, si riflette sia sulla integrità (proteolisi) sia sul livello di 
fosforilazione della caseina. La defosforilazione è una delle modifiche post-
traslazionali più rilevanti dal punto di vista biologico perché, tra l’altro, altera la 
funzionalità della caseina, rendendola meno adatta a caseificazione ed a fungere da 
ingrediente per la preparazione di CPP. In un latte con elevato numero di cellule 
somatiche, è stata dimostrata una spinta degradazione proteolitica ad opera degli 
enzimi idrolitici sia endogeni che derivati dalle stesse cellule somatiche. Abbiamo 
potuto stabilire su base molecolare che latte proveniente da animali affetti da mastite 
è caratterizzato da un profilo caseinico alterato per l’aumento di attività della fosfatasi 
(25) e della plasmina (26), responsabili rispettivamente della defosforilazione e dell’ 
idrolisi delle frazioni caseiniche. Questi tipi di alterazione delle micelle di caseina 
abbassano la qualità del latte alimentare e la resa casearia. Per valutare la qualità 
della caseina in un latte mastitico, abbiamo utilizzato l’HA per valutare la chelazione 
delle fosfoproteine e dei CPP da parte dell’adsorbente. Lo studio con tecniche 
MALDI-MS ed ESI-Q-TOF ha messo in evidenza la comparsa di frazioni caseiniche 
con un ampio intervallo di fosforilazione. Ad esempio, la β-CN 6P e 5P, allo stato 
nativo, si trasformava in proteina con grado di fosforilazione variabile da 6 a 3P. 
Inoltre, è stata rilevata la comparsa di frammenti proteici prodotti dall’azione della 
plasmina e da altri enzimi associati con le cellule somatiche (catepsine, elastasi, etc). 
 I CPP possono essere anche fungere da marcatori di processo. In prodotti 
stagionati come il formaggio Grana Padano, infatti, i CPP subiscono una 
degradazione più o meno spinta ad opera di proteinasi/peptidasi e fosfatasi alcalina 
ed acida, a seconda della zona in cui il campione analizzato è stato prelevato, parte 
esterna o parte interna della forma. La parte centrale del formaggio, durante la 
lavorazione, subisce un’auto-pastorizzazione, mentre la parte esterna, raffreddandosi 
più velocemente dalla temperatura di lavorazione (circa 55° C), contiene livelli di 
fosfatasi residua di circa 10-100 volte superiori. Poiché il Disciplinare di produzione 
del formaggio prevede l’uso di latte crudo, ogni lavorazione con latte pastorizzato 
(attività fosfatasica negativa) produrrà un’attività di fosfatasi uguale, 
indipendentemente dalla zona di prelievo del campione nella forma. In un lavoro 
precedente si era messo in evidenza che nel Grana Padano DOP, le fosfatasi, 
aminopeptidasi e carbossipeptidasi del formaggio producono una progressiva 
defosforilazione e idrolisi dei CPP derivati dall’azione idrolitica della plasmina, fino a 
fornire peptidi contenenti il cluster Ser(P)-Ser(P)-Ser(P)-Glu-Glu, più resistente alla 
digestione enzimatica in vivo di altri peptidi mono-P e di-P (27). La nostra tecnica di 
arricchimento dei CPP mediante l’utilizzazione di HA per lo studio dei CPP nella 
frazione solubile a pH 4.6, ha confermato l’esistenza di un profilo dipendente da una 
diversa attività enzimatica tra parti interne ed zona esterna nelle forme di formaggio 
Grana Padano (28). Abbiamo trovato che il profilo dei CPP riflette il gradiente termico 
centripeto con differenza di raffreddamento tra zone esterne ed interne della forma, 
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con inattivazione centripeta degli enzimi del formaggio. Nella parte esterna della 
forma abbiamo dimostrato che i CPP subiscono una defosforilazione più spinta che 
nelle zone interne.  
 In conclusione, nel corso del dottorato, è stata sviluppata una selettiva tecnica 
di arricchimento di componenti fosforilati, a partire da miscele complesse di proteine 
e peptidi. I peptidi fosforilati della caseina sonostati, poi,  utilizzati per la formulazione 
di un latte funzionale contenente microgranuli di HA-CPP, utili per la cura della carie 
dentaria e per veicolare microelementi (ioni rame, ferro, selenio, etc.). La tecnica 
analitica elaborata è suscettibile di applicazione generale per lo studio del 
fosfoproteoma. Lo studio della fosforilazione proteica ha consentito, inoltre, di 
affrontare uno degli aspetti della qualità delle proteine, sulla base del loro grado di 
fosforilazione. In questa direzione, il metodo analitico si presta a fornire informazioni 
dettagliate sulla valutazione della genuinità di latte alimentare e di formaggio.  
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2. Summary 
 
 In the present PhD work, the results affording the formulation of a new 
functional drink are presented using as nutraceutical component a preparation of 
caseinophosphopeptides (CPP). CPP as well as other source bioactive peptides are 
encrypted within the sequence of a protein. The CPP, produced in vivo or in vitro by 
enzymatic hydrolysis of casein, are phosphopeptides containing SerP or ThrP 
residues occurring mainly in the SerP-X-SerP/ThrP/Glu/Asp clusters where X is any 
amino acid residue except Pro. The phosphorylated cluster sequence Ser(P)-Ser(P)-
Ser(P)-Glu-Glu occurs in most of the CPP, serving as the binding site for di- or 
trivalent minerals. 
We were interested to CPP for their ability to form soluble organophosphate 
salts and may function as mineral carriers, especially for calcium, preventing calcium 
precipitation as insoluble calcium phosphate. This suggests the possibility that CPP, 
increasing solubility of calcium, may enhance absorption of calcium. It has been 
demonstrated that CPP play a key role in bone mineralization and dental enamel 
recalcification.  
 In the first part of PhD work, various chromatographic adsorbents for 
immobilizing metal ion (IMAC) and metal oxide affinity chromatography (MOAC) have 
been evaluated for obtaining phosphorylated peptides in mixtures. However, none of 
the above indicated analytical system is suitable for milk fortification with CPP.  
 In the second part of the thesis, a new selective technique for CPP enrichment 
based on hydroxyapatite (HA) chromatography has been developed for obtaining 
functional milk. This technique is the most appropriate for CPP enrichment using 
casein as source of highly phosphorylated protein. Therefore, casein is particularly 
suitable for the CPP extraction from complex mixtures of phosphocaseins. The 
structure of CPP was determined by MALDI-TOF and LC-MS analysis and confirmed 
by LC-ESI-MS/MS sequencing. Once confirmed the purity of the mixture, CPP in 
semi-industrial scale preparation was realized. In order to reduce production costs, 
HA (HAS) was synthesized and used for the enrichment of CPP using 3 different 
protein mixtures as substrate. The selection of casein, milk proteins or raw milk was 
chosen on the basis of the specific industrial needs. In any case, the HAS-CPP 
complex needed to be finely ground for milk fortifying. Whatever the source of casein, 
the sensory properties of CCP-complex were compatible with the use of the novel 
formulation as functional ingedient. To know the amount of CPP produced in various 
experimental different souces of casein, some CPP were used as internal standards. 
The latter included one-site modified synthetic monophosphorylated αs1-CN (106-
119) and diphosphorylated, αs1-CN (43-58)2P peptides. Using these internal 
standards, the two natural phosphopeptide counterparts were quantified.   
 In the third part of this PhD thesis, the quality of CPP preparation has been 
evaluated. The study has been focused on the casein phosphorylation as index of 
the protein quality. The phosphoproteomic approach has allowed to detect 
abnomalous milk such as the mastitic milk and mechanisms of dephosporylation in 
Protected Denomination of Origin Grana Padano (GP) cheese. In both the cases, the 
composition of pH 4.6 soluble CPP or pH 4.6 insoluble caseins was suitable to 
provide information on milk and cheese genuineness. The phosphoproteomics in the 
presented version should be applicable to a variety of biological systems mainly in 
medicine and biology. 
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3. Introduction 
 
 Milk is rich in a variety of essential nutrients and is considered as a basic food. 
The major bovine milk proteins are classified into two classes: casein and whey 
proteins. The main group of milk proteins are the caseins accounting for ca. 80% 
total proteins milk subdivided into four families named  αs1-casein (34%), β-casein  
(34%), αs2-casein (15%), and κ-casein (14%). Each fractions show genetic 
polymorphism and post-translational modification with phosphorylation and/or 
glycosylation (only κ-casein). All the other milk proteins (ca. 20%) are grouped under 
the name of whey proteins. The major bovine whey proteins are β-lactoglobulin and 
α-lactalbumin. Whey, the pH 4.6 soluble fraction of milk, also contains substantial 
amounts of immunoglobulins (IgGs), serum albumin, which are filtered by the 
mammary gland and secreted into milk. Due to the presence of plasmin, an 
indigeneous endopeptidase of milk, β-casein is processed throughout the N- and C-
terminal end. The C-terminal peptides, designed in the nomenclature as γ-casein, co-
precipitate with native casein by lowerg milk pH to 4.6. The N-terminal peptides, 
called proteose-peptones are heat-stable to heat treatments at variance with whey 
proteins which are very sensitive to heating. Moreover, they are acid-insensitive  
being  the proteose-peptones for the main part phosphorylated peptides.   
Milk has long been considered only as food protein source for young mammals 
because milk proteins are the principal source of amino acids. However, milk 
proteins, in addition to a nutritional role have physiological importance and source of  
biologically active peptides. Bioactive peptides are defined those peptides produced 
in vivo or in vitro by enzymatic hydrolysis exerting in vivo biological functions or 
physiological effects. During the last two decades, the presence of peptides with 
biological activity has been demonstrated. These peptides, which are inactive within 
the sequence of the parent protein, can be released by enzymatic hydrolysis, for 
example, during the gastrointestinal digestion or in the food manufacturing. In 
fermented milk or ripened cheese, proteolysis leads to the formation of various 
peptides, some of which can exhibit themselves a biological activity or as precursors 
cas release active forms of biological peptides. Once they are liberated in the body, 
bioactive peptides may act as regulatory compounds with hormone-like activity. 
These peptides usually contain 3-20 amino acid residues per molecule and their 
function is generated by their particular primary sequence. Thus, these peptides 
represent health enhancer nutraceuticals potentially functional to foods. Although 
other animal, as well as plant, protein contain potential bioactive sequences, milk 
proteins are currently the main source of a range of biologically active peptides1. 
Each milk proteins can be degraded into numerous peptide fragments by enzymatic 
proteolysis and serve as source of bioactive peptides. 
 Increased awareness of the diet-health relationship in many countries has 
stimulated a trend in nutrition science whereby more attention is given to the health 
effects of individual foods. The role of diet and specific foods in the prevention and 
treatment of diseases and improved body functions has become more prominent and 
active. With today’s sophisticated analytical, and biochemical research tools, the 
presence of many other compounds with biological activity has been demonstrated. 
Improvements in separation techniques, in the dairy industry and enzyme 
technology, offer the opportunity to isolate, concentrate or modify biologically active 
compounds (or others), so that their application in functional, dietary supplements, 
nutraceuticals and medical foods has become possible. Potentially, the addition of 
bioactive peptides to the food products could improve consumer’s safety as a result 
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of the antimicrobial property, for example. Lastly, bioactive peptides may function as 
health care products, providing therapeutic value for either treatment of infection or 
prevention of disease2. 
Biologically active peptides are recommended as constituents of the so-called 
‘functional food’ (i.e., food designed in order to obtain the desired functional and 
biological properties) 3,4. Functional foodstuffs are a source of nutrients responsible 
for the physiological aspects of the proper functioning of the body. 
 
4. Bioactive peptides 
 
 It is now well established that physiologically active peptides are produced 
during gastrointestinal digestion and fermentation of food proteins by lactic acid 
bacteria. Bioactive peptides have been defined as specific protein fragments that 
have a positive impact on body functions or conditions and may ultimately influence 
health5. Protein-derived peptides can affect a decrease in blood pressure, inhibit the 
activity of proline endopeptidases, stimulate the functions of the immune system, 
demonstrate opioid agonist and antagonistic activity, induce contractions of smooth 
muscles, inhibit the process of thrombocyte aggregation, exhibit antibacterial, 
fungicidal and surface activity, bind metal ions and participate in mineral transport, 
determine the sensory properties, and improve the nutritive value of foods. A growing 
interest has been observed recently in the use of bioactive peptides for therapeutic 
purposes, especially in treatment with antibiotics and antimycotic agents, as well as 
in therapy of the following pathological states: neoplasms, viral inflammations 
(infections), disorders of the immune systems, neurological and cardiologic 
disorders6. Structural motifs occurring in peptides may serve as a source of 
information to be used while designing new compounds, the so-called 
‘peptidemimetics’ with a similar mechanism of interactions with receptors7 
For this reason, the potential of distinct dietary peptide sequences to promote human 
health by reducing the risk of chronic diseases or boosting natural immune protection 
has aroused a lot of scientific interest over the past few years. The beneficial health 
effects may be attributed to numerous known peptide sequences exhibiting, e.g., 
antimicrobial, antioxidative, antithrombotic, antihypertensive and immunomodulatory 
activities8,9,10. 
4.1 Antithrombotic peptides 
 
 It was discovered that the mechanisms involved in milk clotting, defined by the 
interaction of κ-CN with chymosin and blood clotting processes, defined by the 
interaction of fibrinogen with thrombin, are for several aspects comparable. A large 
number of molecular similarities have been previously reported between these two 
clotting phenomena11. In addition, structural homologies between the undecapeptide 
(residues 106-116, with MAIPPKKNQDK sequence) from bovine κ-casein, and the C-
terminal dodecapeptide (residues 400-411 with HHLGGAKQAGDV sequence) of 
human fibrinogen γ-chain have been reported12. Three amino acid residues (Ile108, 
Lys112, Asp115) of the undecapeptide of κ-casein are in homologous positions as 
compared with the γ-chain sequence of human fibrinogen13. Fibrinogen has a 
bifunctional role in the blood clotting: it participates both in platelet aggregation 
[fibrinogen binds to a specific receptor on the platelet surface: the glycoprotein IIb-IIIa 
complex (GP Ilb-IIIa)] and in fibrin formation14. Casoplatelins, which are κ-casein 
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derived peptides such as f106–116 but also the smaller fragments such as f106-112, 
f112-116, f113–11615, are inhibitors of both the aggregation of ADP-activated 
platelets and the binding of human fibrinogen γ-chain to a specific receptor region on 
the platelet surface16. Furthermore, the κ-casein fragment f103–111 can also prevent 
blood clotting through inhibition of platelet aggregation, but it is ineffective in the 
fibrinogen binding to ADP-treated platelets17. These residues seem to be important 
for the inhibitory effect which is due to the competition between antithrombotic 
peptides and the γ-chain for the platelet receptors. The potential physiological effects 
of these antithrombotic peptides have not been established, but such peptides have 
been detected in the plasma of newborn children after breastfeeding or ingestion of 
cow milk-based infant formulae 18. 
 
4.2 Antihypertensive peptides 
 
Blood pressure regulation is partially dependent on the renin–angiotensin 
system; renin acts on angiotensinogen and releases angiotensin I, an inactive 
decapeptide that is further converted into the hormone angiotensin II, an active 
octapeptide with a potent vasoconstrictor action19, by the angiotensin-converting 
enzyme (peptidyldipeptide hydrolase, ACE) action which removes two amino acids 
from the inactive form. Furthermore this enzyme inactivates bradykinin, which has 
hypotensive activity. (Figure1).  
 
 
 
Figure 1. The renin–angiotensin system 
  
 Angiotensin II has a central role in the regulation of blood pressure and 
vascular structure. Reducing the levels of angiotensin II by ACE inhibition results in 
decreased vasoconstriction, as well as diminished aldosterone secretion which 
decreases the renal output while increasing water retention20. Therefore, inhibition of 
ACE is considered a useful therapeutic approach in the treatment of high blood 
pressure. Much research has been done related to bioactive peptides, and some of 
these studies have been focused on ACE-inhibitory peptides. Several food protein 
sources contain ACE-inhibitory peptides but the main ACE inhibitory peptides derive 
from milk proteins. The peptides obtained from casein are known as casokinins while 
those peptides derived from whey proteins termed lactokinins. The first observation 
about their activity is that the peptides being studied have little or no effect on blood 
pressure of normotensive subjects suggesting that they exert no acute hypotensive 
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effect. Therefore, ACE inhibitory peptides could be applied as initial treatment in 
mildly hypertensive individuals or as supplemental treatment. Another important 
consideration resulted by several in vitro and in vivo assays that is peptides with an 
ACE-inhibitory activity in vitro do not necessarily possess an antihypertensive effect 
after ingestion; the results of these tests have highlighted an important lack of 
correlation between the in vitro ACE inhibitory activity and the in vivo action. In order 
to produce antihypertensive effects in vivo the peptides have to be able to survive 
gastrointestinal digestion, be absorbed intact through the intestine and finally reach 
the cardiovascular system in an active form. It has been reported an increase in ACE 
inhibitory activity by the action of digestive enzymes on fermented casein solution21,22 
In fact it was found that the sequence KVLPVPE (β-casein f169-175), with a low in 
vitro ACE-inhibitory activity was hydrolysed in vivo by pancreatic digestion to the 
potent ACE inhibitor KVLPVP, which was probably responsible for the high 
antihypertensive activity of KVLPVPE in spontaneously hypertensive rats (SHR)23. 
On the contrary, peptides that apparently exhibit in vitro ACE-inhibitory activity can 
fail to show in vivo antihypertensive activity as they are hydrolysed during the 
gastrointestinal digestion. Most of the ACE inhibitory peptides are short sized fomed 
by only two to nine amino acid residues. It has been demonstrated that di- or tri-
peptides, especially those with C-terminal proline or hydroxyproline, are generally 
resistant to degradation by digestive enzymes24,25.  Proline is known to be actually 
resistant to degradation by digestive enzymes26. 
 In addition, short peptides consisting of two or three amino acids are absorbed 
more rapidly than free amino acids27. These peptides can pass the intestinal tract, 
and after absorption, inhibit the production of angiotensin-II in blood. The ACE 
inhibitory tripeptides Val-Pro-Pro (VPP) or Ile-Pro-Pro (IPP), for example, were 
detected in the aorta of SHR, following oral administration of fermented milk28.  
Nakamura et al.29 studied the antihypertensive effect of orally administered doses of 
Calpis  sour milk. Calpis (Calpis Food Industry Co., Ltd., Tokyo, Japan) is a 
Japanese soft drink made from skim milk fermented by Calpis sour milk starter 
containing Lactobacillus helveticus and Saccharomyces cerevisiae. From this sour 
milk two tripeptides (VPP or IPP)  were purified having each a antihypertensive 
activity in SHR rats. The sour milk or tripeptides decreased systolic blood pressure 
6–8h postadministration. 
 Gobbetti et al. 30 demonstrated the formation of ACE-inhibitory peptides with 
two dairy strains, Lb. delbrueckii ssp. bulgaricus and Lc. lactis ssp. cremoris, after 
fermentation of milk separately with each strain for 72h. The most inhibitory fractions 
of the fermented milk mainly contained β-casein derived peptides. The milk 
fermented by L. delbrueckii subsp. bulgaricus SS1 contained the fragments of β-
casein f6-14, f7-14, f73-82, f74-82, and f75-82 while the milk fermented by L. lactis 
subsp. cremoris FT4 contained the sequences of β-CN f7-14, f47-52, and f169-175 
and κ-CN f155-160 and f152-160. 
 The structure-activity relationships of the ACE inhibitory peptides has not well 
studied. However, some general features have been highlighted 31,32,33. The binding 
to ACE is strongly influenced by the C-terminal sequence. In fact ACE appears to 
prefer substrates or competitive inhibitors containing hydrophobic (aromatic or 
branched side chains) amino acid residues at each of the three C-terminal positions. 
It is known that the presence of Pro or lysine or arginine as a C-terminal or 
antepenultimate residue appears to enhance binding. In contrast, ACE binds only 
weakly competitive peptide inhibitors that have penultimate Pro residues34,35. In 
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addition, the presence of the positive charge of Lys (ε-amino group) and Arg 
(guanidine group) as the C-terminal residue may contribute to the inhibitory potency.  
 Furthermore, it has been postulated that the mechanism of ACE inhibition may 
involve the interaction of the inhibitor with subsites not normally occupied by 
substrates or with an anionic inhibitor binding site that is different from the catalytic 
site of the enzyme32. Peptides can adopt different configurations depending on the 
environmental conditions, which determine their bioactivity. Gómez-Ruiz J. A. et al 
have reported the relevance of the conformational structure of the peptide on the 
interaction with the active site of ACE. It seems that peptides containing trans-Pro in 
the C-terminal position are substrate for ACE better than those carrying cis-Pro. The 
carboxyl groups of both trans-Pro and the penultimate residue lie on the same side of 
the peptide chain. In contrast, if proline is in the cis-configuration, these two groups 
are forced to move to opposite sides of the chain. This could lead to the loss of 
interactions with the active site and, in consequence, to a decreased (if any) binding 
to the enzyme and inhibitory activity36.  
 Recently, three novel casein-derived peptides, obtained by pepsin hydrolysis 
of the isoelectric casein have been identified. They corresponded to αs1-CN (f90–94) 
(RYLGY), αs1-CN (f143–149) (AYFYPEL), and αs2-CN (f89–95) (YQKFPQY). They 
showed both potent ACE-inhibitory and antioxidant activity; in particular two of them 
exerted high antihypertensive activity in SHR and their activity was similar to that of  
tripeptide VPP when orally administered at the same dose37.  
4.3 Opioid peptides 
 
 The first, most studied, biologically active casein peptides were the opioid 
peptides with opiate activity. The major opioid peptides are fragments of β-CN, called 
β-casomorphins, due to their exogenous origin and morphine-like properties38. They 
are fragments of β-casein between the 60th and the 70th residues, mainly f60–63, 
f60–64, f60–65, f60–66 and f60–7039. The possess the same N-terminal sequence 
(Tyr-Pro-Phe-Pro) and are characterized as μ-type ligands40. They have been 
obtained from pepsin hydrolysis of bovine αs1-CN 41,42,43. Similar peptides have been 
reported from human β-CN fractions44 and the Y-P-F sequence, which is common to 
bovine β-casomorphin, was also found to be present in the primary structure of 
human β-CN. In general, the αs- and β-CN fragments produce agonist responses, 
while those derived from κ-CN, called casoxins, elicit antagonist effects. In fact they 
suppress the agonistic activity of opioid peptides like enkephalin. Casoxins, found in 
both bovine and human κ-casein as well as in αs1-casein45, act as specific ligands of 
μ- and κ-receptor.  
 The common structural feature among endogenous and exogenous opioid 
peptide (except αs-casein opioids) is the presence of a Tyr residue at the N-terminus, 
and the presence of another aromatic residue, e.g. Phe or Tyr, in the third or fourth 
position. This is an important structural feature, that ensure that the peptide fits into 
the binding site of opioid receptors. The negative potential, localized in the vicinity of 
the phenolic hydroxyl group of Tyr, seem to be essential for opioid activity. Lack of 
the Tyr residue results in a total absence of bioactivity46 while the Pro in the second 
N-terminal position seems to maintain the proper orientation of Tyr and Phe chains 
47. 
 Chabance et al.48 showed that many peptides from αs1-, β-, κ-casein and κ-
caseinomacropeptide exist in the stomach of adults following consumption of milk or 
 12
yoghurt, and some casein fragments were also found in the duodenum. Studies have 
suggested that opioid peptide are formed in the gut as a result of in vivo hydrolysis of 
milk after ingesting of this but, once they are liberated, they are resistant to enzymes 
of the gastrointestinal tract and have been detected in vivo in the intestinal chyme of 
minipigs49 and human small intestines50. Because their absorption in the gut has not 
been observed in adults, it is generally concluded that the physiological influences 
are limited to the gastrointestinal tract with important effects on intestinal transit time, 
amino acid uptake, and water balance51. 
Thus, orally administered opioid peptides may modulate absorption processes 
in the gut and influence the gastrointestinal function in two ways: first, by affecting 
smooth muscles, which reduces the transit time, and second, by affecting the 
intestinal transport of electrolytes, which explains their anti-secretory properties52. In 
contrast, passive transport of β-caseinomorphins across intestinal mucosal 
membranes does occur in neonates, which may experience physiological responses 
such as an analgesic effect on the nervous system resulting in calmness and sleep in 
infants after breast or bottle feeding53.  
4.4 Immunomodulating peptides 
 
 Milk protein hydrolysates and peptides derived from caseins and major whey 
proteins can enhance immune cell functions, measured as lymphocyte proliferation, 
antibody synthesis and cytokine regulation54. Breast feeding facilitates physical 
transmission of passive immunity via a number of multifunctional factors, which have 
a direct effect on the neonate’s resistance to bacterial and viral infections. The most 
important compounds are immunoglobulins, but, in addition, casein are included 
among these factors. In fact, during enzymatic digestion of human and bovine milk 
caseins, peptides with immunomodulating capacities are released. Jolles et al.55 
were the first to report that trypsinised human milk possesses immunostimulating 
activity; in particular, the human milk hexapeptide Val-Glu-Pro-Ile-Pro-Tyr, 
corresponding to β-casein (f54-59) was isolated from its tryptic hydrolyzate56 and 
proven to account for such an activity. It is noteworthy that the hexapeptide 
represents the C-terminal part of β-casomorphin-11. Casein-derived immunopeptides 
including fragments of αs1-casein (residues 194-199; Thr-Thr-Met-Pro-Leu-Trp) and 
β-casein (residues 63-68; Pro-Gly-Pro-Ile-Pro-Asn and 191-193; Leu-Leu-Tyr) 
stimulate phagocytic activity of murine and human macrophages in vitro. Then, the 
pH 4.6-soluble products from the hydrolysis of whole bovine casein by chymosin 
encompass peptides possessing immunomodulatory activity, i.e. αs1-casein f1–23 
and β-casein f193–20957. 
 Furthermore, immunopeptides formed during milk fermentation have been 
shown to contribute to the antitumor effects observed in many studies with fermented 
milks. The peptides released by bacterial proteolysis might have important 
implications in modulation of the host’s immune response and have an impact on 
inhibition of tumor development.58. 
In addition to this, a commercially available caseinophosphopeptide 
preparation (CPP-III), mainly consisting of αs2-casein f1–32 and β-casein f1–28, 
which exert an immunostimulatory action, attributed to the o-phospho-L-serine 
residue has been described, hence suggesting that such a bioactivity is relatively 
stable to proteinase action in the intestinal tract59. 
 Nowadays, mechanism, structure and activity of the immunomodulating 
peptides is still debated. However, an Arg residue at the N- or C- terminal region of a 
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peptide has been suggested to be the leading motif recognizable by specific surface 
membrane receptors60. 
4.5 Antimicrobial peptides 
 
 The antibacterial properties of milk have been known for a long time. In fact, 
the incidence of disease like diarrhoea or respiratory infections are significantly lower 
in breast-fed infants than in formula-fed infants and a variety of protective factors in 
human milk have been claimed to be responsible for this effect. In addition to the 
naturally occurring antimicrobial proteins present in milk, there are also a variety of 
antibacterial peptides encrypted within the sequence of milk proteins that are 
released upon suitable hydrolysis of the parent protein. 
 Lahov et al. (1971) isolated antibacterial glycopeptides released upon cow's 
milk heating. They showed that milk heating followed by chymosin digestion 
produced similar, basic high molecular weight polypeptides called casecidins which 
inhibited the growth of pathogenic bacteria as well as of lactobacilli. Casecidin was 
among the first amongst purified defense peptides and exhibited in vitro activity 
against Staphylococcus, Sarcina, Bacillus subtilis, Diplococcus pneumoniae, and 
Streptococcus pyogenes61. The peptide consisted of the αs1-casein (f1-23) segment, 
named 'isracidin', and was significantly effective in vivo at concentrations that were 
competitive with known antibiotics, as seen in the protection of mice against lethal 
infection by Staphylococcus aureus Smith strain. Field trials showed that injection of 
isracidin into the udder gave protection against mastitis in sheep and cows. Isracidin 
was both therapeutic and prophylactic and produced long-term immune resistance.  
 Casocidin-I (bovine milk), a cationic αs2-CN derived peptide, inhibited 
Escherichia coli and Staphylococcus carnosus62 growth. Two other peptides were in 
the meantime isolated from a peptic hydrolysate of αs2-casein, namely f183–207 and 
f164–179; the former exhibited higher antimicrobial activity than the latter, although 
both possessed comparable hemolytic effects63. The search for antibacterial activity 
from αs2-casein has been extended to milk from other species. 
 Recently, McCann et al.64 have isolated and identified a novel fragment from 
bovine αs1-casein. This cationic peptide (with a theoretical pI 10.46) corresponded to 
residues 99–109 of bovine αs1-casein. This peptide was obtained by submitting 
casein to pepsin hydrolysis and subsequent purification by several steps of 
preparative RP-HPLC. The latter peptide showed activity against the Gram-positive 
bacteria Bacillus subtilis and Listeria innocua. With respect to Gram-negative 
bacteria, (f99–109) presented activity against Salmonella typhimurium, E. coli, Sal. 
enteritidis and Citrobacter freundii. 
 The κ-casein fraction also originated several antibacterial fragments, such as 
kappacin. It is another example of an antimicrobial peptide derived from κ-casein65. 
Kappacin corresponds to the nonglycosylated, phosphorylated form of 
caseinmacropeptide (CMP). In order to characterize the active region of kappacin, 
the peptide was subjected to hydrolysis with endoproteinase Glu-C, seeing that the 
peptide κ-casein A (f138-158) Ser(P)149 was the active form with antimicrobial 
activity against Str. mutans, E. coli and Porphyromonas gingivalis. It is important to 
emphasize that the active form is the phosphorylated and non-glycosylated form, 
since it has been demonstrated that non phosphorylated and glycosylated forms do 
not have any activity against Str. mutans. Other small peptide fragments from κ-
casein have also demonstrated antibacterial activity. 
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 A peptide, called κ-casecidin, has been identified in κ-casein tryptic digests 
and corresponded to κ-casein (f17-21). Chemically synthesized k-casecidin inhibited 
growth of some pathogenic bacteria such as S. aureus, E. coli and Sal. 
typhimurium66.  
 In addition to these antimicrobial peptides, several human and rabbit β-casein 
sequences have been reported to elicit antimicrobial activity. A peptide raising from 
human β-casein was obtained after hydrolysis of human milk with a purified 
proteinase of Lactobacillus helveticus PR467. The peptide corresponded to human β-
casein f(184-210) and showed a large inhibition spectrum against Gram-positive and 
Gram-negative bacteria, including species of potential clinical interest.   
 Trypsin digestion of rabbit casein yielded several peptide fragments with 
antibacterial activity against Gram-positive bacteria68. Of the peptides identified, 
rabbit β-casein (f64-77) was the most active. 
 In general, the mechanisms of action of this kind of peptides is not well known. 
An amphiphilic and a positive net charge are recognised as major structural motifs 
determining the interaction with bacterial membranes, which has been accepted as a 
common target in their mechanism of action. It is recognized that the antibacterial 
activity starts with the electrostatic interaction of cationic peptide with the anionic 
molecules orientated toward the exterior of the cell. This would provide a ready 
explanation for their specificity for bacterial membranes. However, there is 
uncertainty about how these peptides perturb the membrane and whether this 
membrane perturbation is related to their antimicrobial activity69.  
 
4.6 Glycomacropeptide 
 
The glycomacropeptide (GMP) is formed during the enzymatic cheesemaking 
process. In fact, it is released from casein during the enzymatic (rennin or chymosin) 
κ-casein clotting. Chymosin is an aspartyl protease that is secreted in the fourth 
stomach of young mammals having the function of coagulating milk. This enzyme 
hydrolyses  the κ-casein at the Phe105-Met106 bond into two fragments, e.g para-κ-
casein (CMT, residues 1-105) and glycomacropeptide (GMP, residues 106-169). 
Since the C-terminal portion of glycosylated κ-casein molecules is more hydrophilic, 
for O-linked threonine and serine oligosaccharides, GMP is lost in the whey. 
 Many studies over the last 10 years have attempted to establish the potential 
role of GMP and its non glycosylated form, CMP, in regulating the intestinal 
functions70. 
 GMP is known to have many biological functions such as promoting 
bifidobacterium growth71, modulating immune responses72, inhibiting gastric 
secretions and slow down stomach contractions73. 
 It has been suggested that CMP stimulates the release of cholecystokinin 
(CKK), the satiety hormone involved in controlling food intake and digestion in the 
duodenum of animals and humans74. In fact some peptides obtained from pepsin 
hydrolysis induce a satiety effect75 when administered to starving animals; the latter 
effect was similar to that exhibited following cholecystokinin injection. 
 Intact CMP has been detected in the stomach during digestion76 but, on the 
other hand, it has also been observed that GMP can be absorbed as intact and 
partially digested into the circulating blood of human adults after milk or yoghurt 
ingestion77. Based on the above studies, commercial products containing GMP have 
 15
been launched on the market claiming appetite control and weight management 
effect. 
 Moreover, in the recent years the preventive effects of GMP against intestinal 
infection have been also investigated. It is known that specific oligosaccharides are 
involved when infections of patients with bacteria, bacterial toxins and viruses. The 
initial phase of infection is brought about by the adhesion of lectins on the surface of 
bacteria to specific receptors on the intestinal epithelial cells. Mannose and sialic 
acids have been found to be involved in specific receptors78. Hence, such infection 
could be prevented by blocking the adhesion of pathogenic bacteria to the intestinal 
epithelial cells with food components. Since GMP contains sialic acid, it has been 
shown that GMP would be able to bind to pathogenic bacteria thus preventing 
intestinal infection79  
 
5. The object of study of this PhD thesis. Bioactive casein phosphopeptides 
 
 The term phosphopeptide was pioneered by Mellander (1950)80 and it means 
a casein-derived phosphorylated peptide which enhances vitamin D-independent 
bone calcification in rachitic infants. 
 The CPP, produced in vivo or in vitro by enzymatic hydrolysis of casein, are 
casein-derived phosphopeptides containing SerP or ThrP residues that occur mainly 
in the SerP-X-SerP/ThrP/Glu/Asp clusters where X is any amino acid residue except 
Pro. They have different molecular size and most of them contain a common cluster 
sequence of three phosphoseryl groups followed by two residues of glutamic acid, 
Ser(P)-Ser(P)-Ser(P)-Glu-Glu, serving as binding sites for di- or trivalent mineral ions. 
The phosphate residues, corresponding to ca. 30% of the phosphorus content in 
milk, is present as Ser monoesters and the high concentration of negative charges of 
phosphorylated peptides makes them resistant to further proteolysis81. 
Chabance et al.82 have proven the occurrence of CPP in the stomach and duodenum 
following milk ingestion. Certain CPP were for the first time detected in ileostomy fluid 
by Meisel et al. which confirms the ability of such peptides to survive gastrointestinal 
passage to the human distal ileum83. It is also proved that the in vivo formation of 
CPP derived from bovine casein occurred in small intestine chyme of minipigs after 
ingestion of a diet containing casein84.  
 Furthermore, the negatively charged phosphate groups of CPP represent the 
binding site for different minerals. CPP have been shown to bind to different 
macroelements and oligoelements. Phosphopeptides can form soluble 
organophosphate salts and may function as carriers for these minerals, especially 
calcium85. In vitro studies demonstrated that CPP can prevent the precipitation of 
calcium ions as insoluble salts like calcium phosphate86. According to Meisel87, 
binding of Ca involves Ser-bound phosphate groups, as well as the free carboxyl 
groups of Glu; the hydrophobic tail protects this complex from further interactions, 
and hence prevents formation of insoluble calcium phosphate. This suggested the 
possibility that CPP may enhance the soluble calcium amount in the intestinal lumen, 
thereby increasing the mineral availability for absorption in the small intestine88,89,90.  
 The possible influence of CPP on calcium uptake by cultured HT-29 tumor 
cells was assessed by Ferraretto, et al. 91 that directly measured the intracellular free 
calcium concentration, [Ca2+]i, after exposure to different CPP preparations. 
Chemically synthesized CPP, β-casein (f1-25)4P and αs1-CN(f59-79)5P, carrying the 
characteristic ‘cluster SerP motif Ser(P)-Ser(P)-Ser(P)-Glu-Glu, were found to cause 
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an increase of Ca2+ concentration, due to influx of extracellular Ca2+. Moreover, the 
CPP-promoting effect on calcium concentration was proven to depend on the 
structural conformation conferred by both the phosphorylated ‘‘acidic motif’’ and the 
preceding N-terminal portion92. Notably, calcium binding to β-CN(f1-25)4P was 
reported to cause conformational changes to the peptide backbone resulting in a 
loop-type structure of the residues 1-4 (Arg1 to Glu4) and β-turn structure of residues 
8-11 (Val8 to Glu11), 17-20 (Ser(P)17 to Glu20, the ‘acidic motif’), and 21-24 (Glu21 to 
Thr24)93. In the case of αs1-CN(59-79)5P calcium association leads to a β-turn 
structure of residues Pro73 to Val76, and a loop-like structure of residues Glu61 to 
Ser(P)6794 (Figure 2). 
 
 
Figure 2. Primary structure of casein phosphopeptides 
 
 Here, it was demonstrated that the rise of intracellular [Ca2+], is more 
pronounced with the β-casein-derived peptide than with those from αs1-casein . 
Presumably, steric factors due to the amino acids flanking the ‘acidic motif’ contribute 
to the calcium binding ability, as well as other biological properties of CPP, like the 
[Ca2+] intracellular rise effect and immunogenicity95. This tends to suggest that the 
interaction between CPP and the plasma membrane of HT-29 cells, presumably 
instrumental to favour a Ca2+ influx inside the cells, requires a precise peptide 
structure and conformation, where not only the ‘acidic motif’ but also some additional 
polypeptide portions could play pivotal roles96. 
 Moreover, a recent work by Farrell et al.97 showed that the dephosphorylated 
form of β-CN(1-25)4P assumes a much more flexible and dynamic structure, which 
facilitates self-aggregation of the peptide. As a consequence, some motifs on the 
casein phosphopeptide might become cryptic, compromising the functionality of the 
peptide itself. It has been shown by Ferrarretto et al that the ability to take up 
extracellular calcium ions under CPP stimulation is exhibited also by both HT-29 and 
Caco2 cells, but only upon cell differentiation. This evidence adds novel support to 
the notion that CPP favour calcium absorption.98. 
 Furthermore CPP are also capable to effectively bind Mg and Fe, as well as as 
Zn, Ba, Cr, Ni, Co and Se. Iron deficiency, a major worldwide nutritional problem, can 
be reduced by CPP; in fact, binding of Fe to phosphopeptides prevents formation of 
high-molecular weight ferric hydroxides, which are poorly absorbed. In vitro studies 
with rats99 have demonstrated that Fe bound to the phosphoserine residues of low-
molecular weight CPP, as β-casein (f1–25), improved their ability to treat anaemia 
and restore Fe storage tissues, when compared with Fe bound to whole casein and 
inorganic salts. Zinc absorption can also be enhanced if that metal is bound to CCPs, 
in particular β-casein (f1–25)100. 
 CPP have also the ability to stabilize calcium phosphate in solution through 
binding amorphous calcium phosphate with their multiple phosphoserine residues. 
This allows the formation of small CPP-ACP clusters, but without allowing growth to 
the critical size required for nucleation of crystals and subsequent precipitation of 
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calcium phosphate101,102. CPP-ACP have been demonstrated to have anticariogenic 
potential in laboratory, animal, and human in situ experiments103. 
The complex CPP-ACP can significantly enhance the availability of calcium in 
plaque; in fact CPP localize ACP at the tooth surface, inhibiting enamel 
demineralization and promoting enamel remineralization. Tooth enamel is a 
polymeric substance consisting of crystalline calcium phosphate, embedded in a 
protein matrix. Dental caries is initiated via the demineralization of tooth hard tissue 
by organic acids directly assumed with the diet or produced from fermentable 
carbohydrate by dental plaque cariogenic bacteria. Fluoride ions, in the presence of 
calcium and phosphate ions, can help to replace the lost minerals of early caries 
lesions by remineralization. In the development of teeth and bone, it has also been 
shown that phosphopeptides act as nucleators of hydroxyapatite and control the 
growth of the crystals, resulting in a unique crystal morphology characteristic of the 
biological systems.  
 A new calcium phosphate remineralization technology has been developed by 
Reynolds104 based on CPP-ACP [RecaldentTM CASRN691364-49-5]. This CPP 
preparation is claimed to stabilize high concentrations of calcium and phosphate 
ions, together with fluoride ions, at the tooth surface by binding to pellicle and plaque. 
Reynolds (1997) has demonstrated that the complex CPP-ACP can remineralize 
sub-surface lesions in human enamel. In several different studies, the CPP-ACP 
technology has been demonstrated to increase the levels of calcium and phosphate 
ions in supragingival plaque significantly when delivered in a mouthrinse and to 
promote the remineralization of enamel subsurface lesions in situ105. Then, it has 
been also shown that CPP-ACP inhibited the adhesion of cariogenic streptococci as 
Streptococcus mutans to the tooth surface and produced a copious reservoir of 
bioavailable calcium ions106,107. 
 Moreover, it been revealed that yogurt and cheese are also a consistent 
source of bioavailable CPP. Shaw et al.108 observed that ice cream, and cheese 
lowered incidence of dental caries in rats. Elderly people that eat cheese several 
times per week had a lower incidence of root surface caries development109. 
Interestingly, the concentration of CPP in yogurt is higher than that in milk due to the 
proteolytic activity of enzyme micro-organisms.110 Recently, it has demonstrated that 
CPP of yogurt have an inhibitory effect on demineralization and promote the 
remineralization of dental enamel111.  
 Since CPP can be incorporated into foodstuffs as well as therapeutic agents 
and demonstrate none of the adverse effects of fluoride overuse (fluorosis at 
moderate doses and toxicity at higher doses), it is possible to exploit CPP as 
powerful anticaries agents. Hence, it comes our interest for these products as 
nutraceutical ingredients for the formulation of ‘functional foods’. 
 
6. Possible use of CPP for industrial applications  
 
 The “nutriceutical” term is a portmanteau of nutrition and pharmaceuticals and 
it has been coined the first time by Dr. Stephen De Felice (the founder and chairman 
of Foundation for Innovation in Medicine) in 1989. He defined nutraceuticals as “food, 
or parts of food, that provide medical or health benefits including the prevention and 
treatment of diseases”. The term functional food is also used to refer nutraceuticals. 
In the states of Canada and Great Britain, a functional food is essentially a food, but 
a nutraceutic is an isolated form or concentrated form. Achievements in separation 
 18
techniques in the dairy industry and enzyme technology offer the opportunity to 
isolate, concentrate or modify these compounds, so that their application in functional 
foods, dietary supplements, nutraceuticals and medical foods became possible. 
 CPP represent functional substances or bioactive milk components that are 
potential ingredients of functional foods in conjunction with a certain “health claim”. 
These peptides are potential health-enhancing nutraceuticals for food and 
pharmaceutical applications. Numerous claims have been made with respect to the 
application of CPP to enhance mineral bioavailability. For examples, an adequate 
Ca2+supply is required for development or ricalcification following bone fracturing, in 
the prevention of osteoporosis and during the treatment of rickets. Recent studies 
have confirmed the possibility that CPP play a role as modulator of bone cell activity, 
probably sustained by the ability as calcium carriers, for their stimulatory activity on 
osteoblast differentiation and matrix mineralization112. Inadequate Ca2+ levels are 
also implicated in the development of hypertension, colon cancer and kidney stones. 
Lack of adequate dietary Fe2+ can, for example, lead to anaemia. 
 Currently, several multinational companies, particularly in Europe and Japan, 
market CPP containing products aimed at enhancing the bioavailability of mineral 
functional foods. 
 Moreover, calcium CPP are palatable and can be used as an anticariogenic 
additive113. The addition of CPP to toothpaste formulas has been suggested to have 
anticariogenic effects and prevent enamel demineralization114. Laboratory, animal 
and human in situ experiments have demonstrated that synthetic CPP-ACP 
nanocomplexes contained in mouthrinses and sugar-free chewing gums are 
anticariogenic115,116.In fact, CPP have been incorporated into a wide range of 
products such as toothpaste, toothpowder, topical gels, dental filling material, 
mouthwashed, chewing gum, lozenges, tablets, mineral drinks, nutritional 
supplements for children, confectionery, and products for dental care117. 
 CPP-ACP is already being used commercially as an ingredient (RecaldentTM) 
(Table 1) in oral care products. Recaldent is the first product that has been claimed to 
strengthen teeth by increasing remineralisation and protect against decay (dental 
caries). It is an invention by Professor Eric Reynolds from the University of 
Melbourne, Australia and contains CPP and ACP.  
The complex (CPP-ACP) has been incorporated into sugar-free chewing gum as 
Trident White Gum that was marketed in the USA, Japan and four European 
countries. Apart from gums, Recaldent™ (CPP-ACP) is used in paste. In fact the GC 
Corporation has developed a concentrated paste, containing Recaldent™ (CPP-
ACP) that is known as GC Tooth Mousse in most parts of the world and as MI 
(Minimum Intervention™) Paste in the USA and Japan. 
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Table 1 Commercial dairy products and ingredients with health or function claims based on bioactive 
peptides, in particular CPP. 
 
  
7.Techniques for phosphopeptide enrichment for industrial applications 
 
 The first part of PhD thesis was focused on finding a methodology for obtaining 
from the casein hydrolysate a enriched CPP preparation on semi-industrial scale. 
Most commercial CPP preparations contain low quantities of CPP. The product HCP 
102 (Hydrolyzed casein protein 102) obtained from Tatua Cooperative Dairy Co. (Ltd, 
Morrinsville, New Zealand) has been analyzed using mass spectrometry. The product 
is indicated as “an ideal ingredient for products at increased mineral solubility, 
boosted protein levels for quicker nitrogen digestion”. We showed that in a product 
labelled as enriched-CPP preparation, no signal in the MALDI spectrum was 
attributable to phosphorylated peptides as only 16% CPP was present after 
enrichment. Detection problems of CPP might be caused by suppression effects of 
the nonphosphorylated peptides during the ionization process. The ionization of  
phosphorylated peptides is often suppressed in the presence of non-phosphorylated 
peptides as in the normal proteolytic digest of a phosphoprotein118. For matrix-
assisted laser desorption/ionization mass spectrometry (MALDI-MS), desorption/ 
ionization efficiency for phosphopeptides were reported to be an order of magnitude 
lower than those of their nonphosphorylated counterparts, and ionization of 
phosphorylated peptides can become more difficult as the number of phosphorylation 
sites increases. Moreover, these commercial preparations are obtained by hydrolysis 
of different enzymes and not all peptides have Lys and Arg residues as C-terminal 
residue which would increase the ionization efficiency. In fact, it has been 
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demonstrated that the peptides that contain C-terminal lysine, with respect to 
arginine-containing peptides give 4- to 18-fold more intense ions. This could possibly 
be due to the higher basicity of the arginine residue, increasing retention of 
charge119. Therefore, selective enrichment techniques were searched for separating 
phosphopeptides from nonphosphorylated peptides.   
 The first techniques of enrichment consisted in the precipitation of CPP as 
insoluble barium salts and recovery by centrifugation, according to the procedure of 
Manson & Annan120. Current available high-throughput phosphoproteome 
technologies rely on the protein separation by one- or two-dimensional gels 
according to the isoelectric point, digestion with trypsin and analysis of the resulting 
peptides by MALDI-TOF mass spectrometry121. This procedure combines the very 
high resolving power of gel electrophoresis with the sensitivity of mass spectrometry. 
 Recently, methods have been developed for the selective enrichment of 
phosphopeptides based on chemical derivatization and affinity chromatography- 
methods. In the derivatization technique, β-elimination chemistry provides a 
considerably simpler method to enrich phosphopeptides. In this chemistry, strong 
bases such as NaOH or Ba(OH)2 are used to cleave the phosphoester bonds of 
phosphoserine and phosphothreonine to form the respective dehydroalanine or 
dehydroaminobutyric acid analogs, which can react with different nucleophiles, such 
as ethanedithiol, or EDT and can be linked to a biotin affinity tag or a polymer 
support122 (Scheme 1). 
 
Scheme 1. Chemical conversion of a phosphoserine residue to a biotinylated residue. Indicated by the 
dashed line is the position of the facile cleavage (see text) that produces the ion observed at m/z = 
446 in the MS/MS spectra. 
 
 Although the chemical derivatization methods are highly selective, they are not 
widely applied in the phosphoproteome studies for sample loss caused by the 
multiple reaction steps and increased sample complexity by unavoidable side 
reactions123. 
 Several affinity based methods such as immobilized metal ion affinity 
chromatography (IMAC) (with Fe3+, Ga3+, Ni2+and Zr4+ metal ions) and metal oxide 
affinity chromatography (MOAC) (with TiO2, ZrO2, Al2 O3 and Nb2O5) have been 
developed for selective enrichment of phosphopeptides (Figure 3). 
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Figure 3. Schematic diagram of phosphopeptide isolation by IMAC or MOAC. 
 
 IMAC beads immobilized with Fe(III) or Ga(III) are commonly used for the 
purification of phosphopeptides124,125. In this technique, iminodiacetic acid (IDA, a 
tridentate metal-chelator) and nitrilotriacetic acid (NTA, a quadradentate metal-
chelator) are often used as functional reagent that reacts with multivalent metal ions 
to form chelated ions with positive charges. Phosphate groups of phosphopeptides 
with negative charges are attracted by the chelated ions owing to static interaction, 
leading to phosphopeptides retained on the immobilized chelated ions. The 
phosphate group interacts through nonbonding ion pair electron coordination with 
metal ions which have been chelated to a multidentate ligand immobilized onto a 
support material. There is a number of challenges associated to IMAC. First, because 
of the metal ions are not covalently bound to the substrate, there is a possibility to 
leach these ions from the column, during the enrichment steps, which might lead to 
loss of phosphopeptides or to a contamination of peptides with metal ions. A second 
challenge is nonspecific binding of peptides that contain the acidic glutamic and 
aspartic acid residues. Methyl esterification of carboxyl groups has been 
demonstrated to decrease the nonspecific adsorption of acidic peptides on IMAC126. 
 Instead of using IMAC with Fe3+, higher specificity and lower sample loss was 
observed for MOAC, using some metal oxides such as TiO2 and ZrO2. The negatively 
charged phosphopeptides selectively interact with titansphere via bidentate binding 
at the dioxide surface127,128,129. However, the selectivity of this method was somewhat 
compromised by the detection of several acidic non-phosphorylated peptides that 
were also retained by their TiO2 column. 
 Considerable efforts have been made to improve this technique. Significant 
improvement was obtained in MOC with titania when benzoic acid derivatives such 
as 2,5-dihydroxybenzoic acid (DHB)130  and phthalic acid131 were used in the sample 
loading buffer to eliminate acidic nonphosphorylated peptides. Recently, it has been 
found that aliphatic hydroxyl acid-modified metal oxide works more efficiently and 
more specifically than aromatic modifiers such as DHB and phthalic acid in titania 
and zirconia MOC132. 
 In several studies the combination of different enrichment methods has been 
found to be advantageous for selective phosphopeptide enrichment as the coupling 
of two complementary enrichment methods as calcium phosphate precipitation and 
 22
IMAC133, or as SCX and SAC where protein digests were first loaded on an SCX 
column, and the flow-through peptides from SCX were collected and further loaded 
onto a SAX column134. 
 However, none of the tested analytical systems could be applied in industrial 
field for three reasons: a) the resin to which CPP are linked is not edible and barium 
chloride, in the procedure of Manson & Annan, is hazardous reagent and large 
quantity of expensive ethyl alcohol makes the procedure unrealiable, b) the elution of 
CPP from the resin requires very long and expensive purification systems, c) 
fortification of  foods with eluted CPP alter the taste, making it more bitter. This is 
principally due to the ability by CPP to chelate mineral ions from contacting matrix.  
 
8. Development of a new enrichment technique 
 
 In the second part of the PhD work, a new technique for specific 
phosphoproteins and phosphopeptides enrichment from complex mixtures have been 
developed. The objective is to set out an analytical method for CPP enrichment to 
use for preparative purpose of nutraceuticals in functional foods. Using inexpensive, 
raw materials free of harmful Ba, Fe, Ga, Ni, Zr and Ti compounds, a large scale CPP 
isolation was obtained. Chromatography on industrial scale is based on ion exchange 
columns separation of great diameter or, to avoid the problems of clogging, on batch 
processes. The used material consists of a resin having the capacity of binding anion 
compounds such as CPP carrying negative charges in a wide pH range. This high 
selectivity technique is based on hydroxyapatite (HA) chromatography. HA is a form 
of calcium phosphate with the formula [Ca10(PO4)6(OH)2] which can be used as 
chromatographic matrix. HA chromatography is considered to work as a “mixed 
mode” ion exchange or a “pseudo-affinity” chromatography. The functional groups 
comprise positively charged pairs of crystal calcium ions (C-sites) and clusters of six 
negatively charged oxygen atoms associated with triplets of crystal phosphates (P-
sites). The hydroxyapatite/biomolecule interactions are complex. Generally, it is 
thought that amino groups are attracted to negatively charged P-sites and repelled by 
positively charged C-sites. The opposite is true for negatively charged, 
phosphorylated residues of proteins. (Figure 4)  
. 
 
 
Figure 4. Protein binding to hydroxyapatite. Double parentheses indicate repulsion. Dotted lines 
indicate ionic bonds. Triangular linkages indicate coordination bonds. 
 
 The more phosphates are present, the more dominating is the calcium site 
binding and thus the tighter is the binding of the protein to the matrix135 
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Phosphorylated groups on proteins and other solutes interact even more strongly 
with C-sites than do carboxyls136. This is reflected in extremely strong binding by 
proteins and peptide with high degree of phosphorylation. Then several studies 
demonstrated that phosphorylated proteins bind more strongly to HAP than their 
unphosphorylated counterparts137.  
 The developed method employs ceramic hydroxyapatite (HA) as solid-phase 
adsorbent to separate nonphosphorylated from resin-bound phosphorylated 
components. Casein was chosen as phosphorylated protein model. Phosphopeptide 
was obtained by tryptic digestion in situ on HA-casein complexes. 
   
9. Experimental procedure 1 
 
Materials 
 
 Raw whole milk was collected from local dairy farms. Milk was skimmed by 
centrifugation at 4,000 rpm at 4° C for 30 min. Isoelectric casein was prepared by 
adding to skim milk 10% (v/v) acetic acid, allowing to stand 30 min at 35° C and then 
adding 1M NaOAc to 4.6 final pH.  After standing for 30 min, suspension was 
centrifuged (4,000 rpm, 5° C for 30min), the supernatant discarded, casein washed 
twice with buffer diluted 1:4, twice with water Milli-Q, and subsequently freeze dried. 
HA (Macro-Prep Ceramic Hydroxyapatite TYPE I, catalog number 157-0040) was 
purchased from Bio-Rad (Milan, Italy). Tris (hydroxymethyl) aminomethane 
hydrochloride (Tris-HCl), potassium chloride (KCl), urea, trifluoroacetic acid (TFA), 
acetonitrile (ACN) for HPLC Plus, orthophosphoric acid 85% were from Carlo Erba 
(Milan, Italy).Trypsin TPCK treated from bovine pancreas was from Sigma (St. Louis, 
MO, USA). Sodium acetate trihydrate, 2,5-dihydroxybenzoic acid (DHB) were from 
Fluka (St. Louis, MO, USA). Acetic acid was purchased from Baker Chemicals B.V. 
(Deventer, The Netherlands). Dithiothreitol (DTT) was from Applichem (Darmstadt, 
Germany). Water was prepared using a Milli-Q system (Millipore, Bedford, MA, USA). 
 
HA-based phosphoprotein/peptide enrichment  
 
 Casein (10 mg) was dissolved in 80μl buffer at pH 8.0 containing TrisHCl 50 
mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM. The casein solution was loaded on HA (10 
mg), previously equilibrated in the loading buffer. The HA-bound casein was 
incubated for 15 min at room temperature and centrifuged for 5 min at 4,000 rpm. 
The resin was washed in succession with three buffers, i.e. the loading buffer (1ml); 
washing buffer at pH 7.8 containing Tris-HCl 50mM (1 ml); and 20mM Tris-HCl (pH 
7.8) buffer containing 20% ACN (v/v)(1ml). The resin washed with water Milli-Q (1ml) 
and finally freeze-dried with a SpeedVac concentrator system (Thermo Electron, 
Milford, MA).   
 
HA-based CPP enrichment 
  
 The HA-bound phosphoproteins were hydrolyzed in situ with trypsin added to 
the suspension at an enzyme/substrate ratio of 1:50 (w/w) in 50mM Tris-HCl buffer, 
pH 8.0, containing 0.2 M KCl, 4.5M urea, and 10 mM DTT. The reaction was carried 
out at 37° C overnight and stopped by centrifuging the HA-CPP microgranules for 5 
min at 4,000 rpm. Then, the microgranules were washed as described above for 
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phosphoproteins. After washing with water Milli-Q, they were dried by using a 
SpeedVac apparatus.  
  
MALDI-TOF MS Analysis  
 
 MALDI-TOF mass spectra were recorded using a Voyager DE-PRO mass 
spectrometer (Applied Biosystem, Framingham, USA), in positive linear mode. All 
spectra were acquired in the range of 15–30 kDa (for proteins) and 1–5 kDa (for 
peptides) with the following settings: an accelerating voltage 25 kV (for proteins), and 
20 kV (for peptides)  and grid voltage 93% (for proteins) and 95% (for peptides) of 
accelerating voltage, a guide wire of 0.15% (for proteins) and 0.05% (for peptides), 
delayed ion extraction time of 485 (for proteins) and 175 ns (for peptides). The laser 
power was set just above the ion generation threshold to obtain peaks with highest 
possible signal to noise ratio. All spectra were acquired with 200 shots in 3 replicate. 
Two different matrix solutions were freshly made each day using stocks of the 
required solvents and sonicated for 15 min in an ultrasonic water bath prior to use. 
The sample/wash (SW) method was based on the sample/matrix/wash (SMW) 
method described by Zhang et al.138 with the exclusion of the wash step. The matrix 
for phosphoprotein analysis was constituted by sinapinic acid (SA) solution at 10 
mg/mL in 50% ACN and 0.1% TFA. 1 μL of sample was added to spot and allowed to 
dry. The matrix for phosphopeptides contained 2,5-dihydroxybenzoic acid (2,5-DHB), 
10 mg/mL in 1 ml of  H2O/ACN/PA (49/50/1). 1 μL of sample was added to spot and 
allowed to dry. The HA-phosphoprotein microgranules were deposited onto the 
MALDI plate and covered with the SA matrix (10 mg/ml in 50% ACN) to promote 
analyte/matrix co-crystallization in presence of increasing TFA concentration (0.01%, 
0.05%, 0.1% and 0.5%) for proteins.  For CPP, 1% phosphoric acid (PA) was 
included in the DHB solution (10 mg/ml SA in 50% ACN)139.    
 
Microscopic observation 
 
 The HA-CPP microgranules deposited onto a 96-well  MALDI target were 
observed by stereomicroscopy before and after co-crystallization with the DHB 
matrix. The microscope (PBI International, Milan, Italy) was equipped with a binocular 
head illuminated with a 6 V, 20 W halogen lamp and 100-230 V, 50/60 Hz power 
supply 
 
LC/MS Analysis 
 
 LC/MS spectra were obtained by means of an Agilent 1100LC/MSD single 
quadrupole instrument. HA-CPP complexes (1 mg) were solubilized with 120 μl of 
solution containing 0.5% PA and 100 μl of this solution were then injected. For this 
analysis, HA-CPP complexes of caseins were fractionated using a Vydac C18 
218TP52 column (250mm-2.1mm i.d.), at a constant flow rate of 0.2 mL/min. Elution 
was carried out with a linear gradient from 5% to 90% of solvent B (0.1% TFA in 
acetonitrile, v/v) over 100 min after 15 min of isocratic elution at 5% B; solvent A was 
0.1% TFA in water (v/v). Liquid effluents from the column were directly injected into 
the source of a LC/MSD SL (Agilent Technologies) single quadrupole mass 
spectrometer. The mass spectra were scanned from m/z 1600 to 400 at a scan cycle 
of 4.90 s/scan and 0.1 s inter-scan delay. The source temperature was 180°C. 
Spectra were acquired in positive ion mode, where the capillary voltage and the cone 
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voltage were 3.6 kV and 40 V, respectively. N2 was used as both the drying and 
nebulising gas.  
 
LC-ESI-MS/MS Analysis  
 
 HA-CPP complexes (1 mg) were solubilized with 120 μl of 0.5% PA and 
analyzed by a CapLC nano-flow high-pressure pump system (Waters) interfaced with 
a QTOF Micro mass spectrometer (Waters/Micromass) operating in the positive ion 
mode. Chromatographic separations were performed on a reverse phase Atlantis 
dC18 capillary column (75 μm i.d.). The mobile phase was water (A) and ACN (B) 
with 0.1% FA. A linear gradient from 5 to 70% of B was applied over 45 min at a flow-
rate of approximately 300 nL/min using a precolumn split with a pump operating at 5 
µl min-1. The source conditions were as follows: capillary voltage, 2.6 kV; cone 
voltage, 100 V; and RF1 lens, 40 V. In the ESI-MS/MS experiments for peptide 
sequencing, argon was used as the collision gas. Raw data were processed using 
MassLynx 3.5 ProteinLynx software.  
 
 
10. Results and discussion 
 
 The analytical method which finally was adopted can be summarized in the 
following six consecutive steps: (1) selective enrichment of the 
phosphoproteins/phosphopeptides on HA microgranules (resin:protein 1:1, w/w) from 
protein mixtures, (2) flow-through of the unphosphorylated components using the 
dilution/washing buffer, (3) drying the protein/peptide-HA microgranules, (4) loading a 
few dried HA microgranules (~1000) on the MALDI target plate; (5) covering with the 
sinapinic acid or DHB matrix with acid solution (TFA) or (PA) respectively which co-
crystallise with HA microgranules and (6) in situ desorption of the bound HA-
phosphoproteins/phosphopeptides by direct MALDI/MS analysis (Figure 5).  
 
 
   
                                                           = phosphate group   
 
 It resulted a highly sensitive and selective method with good reproducibility for 
extraction and enrichment of phosphorylated proteins and peptides. The 
unphosphorylated components including γ-CN and nonphosphorylated peptide like 
αs1-CN (f91-100) (m/z 1267), and αs1-CN (f8-22) (m/z 1759) were removed from the 
resin in the washing buffer. Inclusion of 20% ACN in the Tris-HCl buffers greatly 
Figure 5. Schematic representation of 
the technique of HAP-based 
phosphoproteins/peptides enrichment. 
Phosphoproteins/peptides were bound 
to the HAP through their phosphate 
groups, the non phosphorylated 
components were removed  using 
washing buffers The dried HAP-
phosphoproteins were analysed directly 
by MALDI–TOF after co-crystallization 
of the sinapinic acid with an appropriate 
quantity of trifluoroacetic acid. 
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weakened ionic interaction between peptides and HA, which facilitated their release 
from the adsorbent resin. Moreover, using the Tris-HCl buffer at pH 7.8, the positively 
charged amino group of Tris was protonated and it competed with the peptides for 
binding to the negatively charged phosphate groups of the resin in order to weaken 
the bond between the amino groups of peptides and phosphate groups of the resin.  
 Therefore, some experiments were directed to optimize the separation of 
mono-phosphorylated and multiply phosphorylated proteins in separate pools. The 
HA-phosphoprotein microgranules were deposited onto MALDI plate and covered 
with sinapinic acid matrix (10 mg/ml in 50% ACN) to promote analyte/matrix co-
crystallization, in presence of 0.01-0.5% TFA (Figure 6). It has been observed that 
the inclusion of 0.01% TFA in the MALDI matrix resulted in the ionization of 
phosphoproteins with a lower degree of phosphorylation as κ-CN 1P and β-CN 
(Figure 7, panel a). 0.1% TFA produced simultaneous ionization of all the casein 
components, i.e. κ-CN 1P, β-CN A1 and A2 variant, 4P and 5P, αs1-CN 8P and 7P, 
and αs2-CN 11P and 12P (Figure 7, panel b). TFA concentration beyond 0.01 and 
0.1% did not afford different protein recovery. Using 0.005% TFA, κ-CN 1P was 
almost exclusively desorbed distinctly from the more phosphorylated components 
(not shown). Using 0.5% TFA concentration in the MALDI matrix did not afford higher 
recovery of protein.  
 
      
Figure 6. Representation of co-
crystallization of HAP-bound casein 
with sinapinic matrix on the target in 
the presence of 0.01%, 0.05%, 0.1% 
and 0.5% TFA 
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Analysis of phosphopeptides 
 
 For the isolation of CPP, well rinsed HA-casein microgranules in suspension 
were submitted to hydrolysis in situ by overnight trypsin treatment. The resulting 
microgranules were separated by centrifugation and cleansed through mixing the 
equilibration/washing buffer to ensure that the enzyme action was stopped. The 
nonphosphorylated peptides were eliminated by washing buffers as illustrated in the 
Figure 8. 
 
 
                         = phosphate group 
 
 We raised the problem of determining which peptides remained tightly bound 
to the resin. Hence, a system of quality control of CPP preparation was developed, 
using mass spectrometry techniques such as MALDI/MS, LC-ESI/MS and LC-ESI-
MS/MS. We demonstrated that each of these techniques allows to characterize the 
CPP bound to the resin. The study showed that the resin immobilizes a plethora of 
peptides, including CPP with multiple phosphorylation site of the type αs1-CN (f59-79) 
5P (f2720.91 Da), β-CN (f1-25) 4P (3122.26 Da) and αs2-CN (f46-70) 5P (3087.99 
κ-CN 1P β-CN 5P
κ-CN 1P 
β-CN A1 5Pαs1-CN 8P
αs2-CN 11P
β -CN A2 5P
αs1-CN 7P
β -CN A1 e A2 4P
αs2-CN 12P 
a  
b  
Figure 7. MALDI MS spectra of 
casein eluted with 0.01%TFA (a) 
and 0.1%TFA (b) 
Figure 8. Schematic 
representation of the HAP-based 
CPP enrichment technique. HAP-
bound phosphoproteins were 
hydrolyzed in situ by trypsin. Non 
phosphorylated peptides were 
washed out in the flow-through. 
The dried HAP-CPP 
microgranules included in the 
crystallime matrix were analysed 
by MALDI-TOF directly on the  
MALDI plate.          
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Da), each containing the sequence cluster Ser(P)-Ser(P)-Ser(P)-Glu-Glu, functional 
to metal ion transport. A rapid analytical technique has been developed for the 
identification of the CPP. The HA-CPP microgranules were co-crystallised onto the 
well MALDI plate included into DHB matrix solution and phosphoric acid. Inclusion of 
1% phosphoric acid allowed to achieve the maximum ionization efficiency by MALDI 
and minimize binding of CPP to HA. Kjellstrom, S and Jensen, O. N.139 reported that 
phosphoric acid (PA) was proved to be the matrix additive chosen for the sensitive 
detection of phosphopeptides. PA actually worked well in enhancing the 
phosphopeptide signals. 
 The microscope images of HA-CPP on well MALDI plate before and after 
crystallisation are shown in Figure 9. 
 
                                 
 
Figure 9. The microscopic images of HA-CPP on well MALDI plate before (a) and after crystallisation 
(b) of HA-CPP microgranules with DHB matrix in PA solution. 
 
 The MALDI spectrum of HA-CPP complexes is shown below (Figure 10). An 
enlargement in two spectra has been obtained for marking the corresponding CPP to 
every peak (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b 
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Figure 10. MALDI mass spectrum of HA-CPP complexes loaded directly on the well MALDI plate after 
enrichment. An enlargement in two spectra has been underlined. 
 
 The overnight incubation and high trypsin-to-substrate ratio 
(resin/enzyme=1/50) produced the maximum yield of tryptic peptides. Protein binding 
via Lys and Arg residues to negatively charged P-sites of HA would mask most of the 
casein sites to trypsin. In contrast, binding of phosphate groups to HA was chosen as 
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casein remained as susceptible to trypsin and produced tryptic CPP of ideal size for 
mass spectrometry analysis. The presence of basic amino acids Arg and Lys in C-
terminal position also facilitates subsequent mass spectrometric analysis. In spite of 
this, from the proteolytic digests of casein about thirty CPP were identified, including 
some phosphopeptides with missed cleavages (Table 2). The list of the theoretical 
tryptic CPP annotated in the Swiss Prot archives and their molecular masses is 
shown in the Table 2. Tryptic phosphopeptides were identified by comparing the 
measured mass with that derived from the standard casein sample. 
 
Table 2. Identification of CPP bound to the HA microgranules loaded directly on the well MALDI plate 
after enrichment. 
Molecular Mass (Da) 
NATIVE CPP 
Expected  Measured MH+ Peptide identification   Missed cleavages CPP 
1410.5 1411.6 αs2(f126-136)2P 
 
1466.5 1467.6 αs2(f138-149)1P 
1538.6 1540.3 
 
αs2(f126-137)2P 
1594.7 1595.6 αs2(f138-150)1P 
1659.8 1661.6 αs1(f106-119)1P 
 
1846.7 1847.1 αs1(f43-58)1P 
1926.1 1928.3 αs1(f43-58)2P 
1952.0 1952.3 αs1(f104-119)1P 
2060.8 2062.8 β(f33-48)1P 
2080.4 2079.4  αs1(f103-119)1P 
2539.4 2538.6 αs2(f2-21)3P  
2598.0 2598.1  αs1(f37-58)2P 
2618.9 2619.3 αs2(f2-21)4P  
2678.0 2678.3  αs1(f37-58)3P 
2703.9 2703.8 αs1(f59-79)5P pyroQ 
 
2720.9 2720.9 αs1(f59-79)5P 
2746.9 2747.6 
 
αs2(f1-21)4P 
2855.2 2855.4 αs1(f35-58)2P 
2886.2 2886.0 β(f2-25)3P  
2935.2 2935.2  αs1(f35-58)3P 
2966.2 2966.0 β(f2-25)4P 
 3088.0 3087.0 αs2(f46-70)5P 
3007.9 3007.3 αs2(f46-70)4P 
3122.3 3122.1 
 
β(f1-25)4P 
3042.3 3043.8 β(f1-25)3P 
3132.1 3131.4 αs2(f1-24)4P 
3477.5 3477.0 β(f1-28)4P 
3605.6 3605.1 β(f1-29)4P 
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 LC/MS analysis of samples enriched in phosphopeptides was also carried out 
to verify purity of the preparation and the correctness of peptide assignment. The LC-
ESI-MS TIC profile (Figure 11) and identification of the chromatographic peaks are 
reported in Table 3.  
 
 
 
Figure 11. LC-MS chromatogram of CPP bound to the HA microgranules dissolved with an aqueous 
solution containing 0.5% PA  
 
Dissolution of HA in 5% PA (w/v) solution has been carried out to ensure that 
all CPP bound were actually eluted from the resin. 
 
Table 3. Peptide identification of each chromatographic peak of CPP bound to the HA microgranules 
dissolved with an aqueous solution containing 0.5% PA.  
 
Peak Number Theoretical mass (Da) Measured mass (Da) Peptide identification 
1 1410.49 1410.82 αs2-CN (f126-136)2P 
2 1538.59 1538.04 αs2-CN (f126-137)2P 
3 1942.70 1943.00 αs1-CN (f43-58)2P M(0) 
4 
2061.01 2061.59 β-CN (f33-48)1P 
2720.90 2720.90 αs1-CN (f59-79)5P 
5 
2720.90 2720.98 αs1-CN (f59-79)5P 
3007.90 3008.04 αs2-CN (f46-70)4P 
6 3007.90 3008.04 αs2-CN (f46-70)4P 
7 
3004.09 3004.26 αs2-CN (f2-24)4P 
2618.89 2618.97 αs2-CN (f2-21)4P 
1 2 
3 
4
5
6
7
8
9
11 
10
12
13
14
15
16
17
18
19
20 
mAU 
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2431.06 2431.86 β-CN (f30-40)1P 
8 1926.68 1927.32 αs1-CN (f43-58)2P 
9 
1465.60 1465.40 αs2-CN (f138-149)2P 
1846.70 1847.00 αs1-CN (f43-58)1P 
10 
2935.19 2935.29 αs1-CN (f35-58)3P 
2678.02 2678.03 αs1-CN (f37-58)3P 
11 
2598.05 2598.10 αs1-CN (f37-58)2P 
2855.19 2855.20 αs1-CN (f35-58)2P 
12 1659.80 1660.33 αs1-CN (f106-119)1P 
13 
 
1951.95 1951.62 αs1-CN (f104-119)1P 
3449.47 3448.64 β-CN (f2-29)4P 
14 3122.26 3122.42 β-CN (f1-25)4P 
15 3122.26 3122.42 β-CN (f1-25)4P 
16 
2966.16 2966.22 β-CN (f2-25)4P 
3122.26 3122.42 β-CN (f1-25)4P 
17 
3477.48 3477.83 β-CN (f1-28)4P 
3605.06 3605.30 β-CN (f1-29)4P 
18 
3042.26 3043.32 β-CN (f1-25)3P 
2966.16 2965.83 β-CN (f2-25)4P 
3122.26 3121.13 β-CN (f1-25)4P 
19 
3042.26 3042.34 β-CN (f1-25)3P 
2886.16 2886.17 β-CN (f2-25)3P 
20 2886.16 2886.29 β-CN (f2-25)3P 
 
 
 The results of the LC-MS analysis underline the presence of αs2-CN (f2-24)4P 
(3004.09 Da) which was masked by the more abundant signal of αs2-CN (f46-70)4P 
(3007.90 Da). It is possible to observe also the presence of the β-CN (f2-29)4P 
(3449.47 Da) peptide whose ionization was suppressed from that of the most 
abundant peptides in MALDI spectrum. 
 The fragmentation spectra obtained with ESI-MS/MS allowed to confirm the 
CPP bound to the HA and to identify the sites which underwent dephosphorylation. 
For example, the spectrum of Figure 12 shows the fragmentation of αs1-CN (f43-
58)2P peptide having the amino acid sequence NH2-Asp-Ile-Gly-pSer-pSer-Glu-Thr-
Glu-Asp-Gln-Ala-Met-Glu-Asp-Ile-Lys-COOH and molecular mass of 1926.7Da 
containing two serine residues (Ser46 and Ser48) both phosphorylated while 
phosphorytable Thr49 was unphosphorylated. 
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Figure 12. MS/MS spectrum from fragmentation of the doubly charged precursor ion at m/z 964.31. 
The product ions belonging to the y series is indicated. The fragmentation spectra were processed by 
the MaxEnt 3 program to a singly charged spectra and were elaborated using the ProteinLynx 
software.  
 
 The ions y10 (1179.51 Da) and y11 (1346.51 Da) with molecular mass variation 
(∆m) of 167 Da (Ser + H3P04) indicate the fragmentation of phosphorylated Ser48 
(11th position from the C-terminal), the ions y12 (1475.55 Da) and y13 (1642.55 Da) 
with ∆m of 167 Da (Ser + H3P04) indicate the fragmentation of phosphorylated Ser46 
(13 th amino acids from the C-terminal). 
 The fragmentation of the peptide α s1-CN (f43-58)1P with amino acid 
sequence NH2-Asp-Ile-Gly-Ser-Glu-pSer-Thr-Glu-Asp-Gln-Ala-Met-Glu-Asp-Ile-Lys-
COOH and molecular mass of 1846.74 Da included only one phosphate group on 
Ser48, whereas Ser46 remained free (Figure 13).  
 
 
%
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Figure 13. MS/MS spectrum from fragmentation of the doubly charged precursor ion at m/z 924.38. 
The product ions belonging to the y series is indicated. The fragmentation spectra were processed by 
the MaxEnt 3 program to a singly charged spectra and were elaborated using the ProteinLynx 
software.  
 
 The ions y10 (1179.51 Da) and y11 (1346.51 Da) with ∆m of 167 Da (Ser + 
H3P04) indicate the fragmentation of phosphorylated Ser48 (11th amino acids from the 
C-terminal), the ions y12 (1475.55 Da) and y13 (1562.59 Da) with ∆m of 87Da (Ser) 
indicate the fragmentation of not phosphorylated Ser46 residue (13th position from the 
C-terminal) 
 The ESI Q-TOF analysis of the phosphorylated mixture confirmed the 
presence of the peptide αs1CN (f43-58) with one degree of phosphorylation. Thus this 
peptide confirms the copresence of native casein αs1-CN 7P and αs1-CN 8P. 
 These experiments allowed to confirm the selectivity and specificity of the 
resin and the purity of the mixture obtained by applying the outlined analytical 
technique. At that time, it was assayed to transfer from the laboratory to pilot scale 
the HA-CPP complex for functional milk formulation. 
 
 
 
MH2+
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11. Formulation of a functional drink in semi-industrial scale 
  
 The laboratory technique was transferred to semi-industrial scale. First at all 
the development of an industrial process implies the use of inexpensive raw 
materials. Thus, we planned the preparation of the complex HA-CPP in semi-
industrial scale by de novo synthesizing HA, owing to the expensive commercial 
product. Therefore, HA was synthesized by wet-chemical precipitation reactions from 
Ca(OH)2 and H3PO4 solution, adopting temperature and pH optimum for obtaining 
pure crystals of apatite. The absorbent activity of the synthesized resin (HAS) was 
evaluated by comparing the binding capacity of CPP in 3 different proteins mxtures, 
e.g. isoelectric casein, milk proteins (casein + whey proteins) and raw milk. Milk 
proteins, commonly used in the dairy industry or raw milk were directly loaded on HA. 
After opportune washings, casein-HA and tryptic derived CPP were compared to 
those recovered by using isoelectric casein. We demonstrated that protein material 
loaded on HA could be variable depending on specific needs because the same CPP 
were linked to HAS from isoelectric casein, milk proteins and raw milk. For functional 
milk preparation, tryptic hydrolysis of in situ bound protein was operated on the HAS-
casein suspension. There were CPP tightly bound to HA, and non-phosphorylated 
peptides removed from the resin by repeated washing buffers, until a washed product 
in milliQ water was obtained. The HA-CPP microgranules were then dried for the 
storage of the powder for times of the order of years at room temperature. Dried 
microgranules of HA-CPP complex were also analysed by MALDI. Then, dried 
microgranules were ground before addition to milk. The flow diagram of preparation 
of functional milk is shown below (Scheme 2). 
  
 
 
 
 
 
Scheme 2. Flow diagram of functional milk preparation 
 
 
 
 
 
 
 
 
 
HAS Synthesis 
Loading 
protein on HAS
Tryptic digestion 
in situ
Drying
Rapid MALDI 
Analysis on 
well plate 
Grinding  
Addition the 
suspension to 
milk 
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nonphosphorylated 
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12. Experimental procedure 2 
 
Materials 
 
Raw whole milk was collected from local dairy farms. The skimmed 
pasteurized milk was supplied by YMA industry. Milk proteins powder were from 
Sacco industry (Milan, Italy). Calcium hydroxide was purchased from Carlo Erba 
(Milan, Italy). The source of the other raw materials has already been above 
indicated. 
 
HA Synthesis  
 
HA was precipitated using this following reaction scheme. 
 
5Ca(OH)2 + 3H3PO4                  Ca5(PO4)3(OH) + 9H2O 
 
12.5 mmol or 925 mg of Ca(OH)2 powder in 125 mL of milliQ water and 7.5 mmol or 
865 mg of 85 wt%H3PO4 in 125 mL of milliQ water were used for the HA 
precipitation. The orthophosphoric acid solution was added in a dropwise manner to 
a dilute solution/suspension of calcium hydroxide. Prior to PO43- ion addition to the 
Ca2+ ion solution, the latter was heated to 90°C and stirred for 1h at 400 rpm. The 
acid was added at a rate approximately equal to 3.5 mL/min using a peristaltic pump. 
The reaction was maintained under constant stirring to ~400 rpm at room 
temperature for 2h. The precipitation reaction was slow and proceeded at 4°C 
overnight. The precipitate was filtered, washed with milliQ H2O for 3 times and dried 
in an oven at 60° C. 
 
Application of the synthetic HAS to isoelectric casein, milk protein and raw 
milk 
 
The binding capacity of the synthesized HAS was evaluated by comparing the 
MALDI spectra of CPP from 3 different proteins mixture, e.g. isoelectric casein 
(sample 1), milk proteins (sample 2) and raw milk (sample 3).  
Sample 1: 1 g casein was dissolved in 8 ml of buffer at pH 8.0 containing Tris-HCl 50 
mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM. The protein solution was loaded on 1 g of 
synthesized HA (ratio HA/protein=1/1), previously washed with loading buffer. 
Sample 2: 1g milk proteins was dissolved in 8 ml of pH 8.0 buffer containing Tris-HCl 
50mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM. The protein solution was loaded on 1g of 
synthesized HA (ratio HA/protein=1/1), previously washed with loading buffer. 
Sample 3: 31.2 ml of raw milk was loaded on 1 g of synthesized HAS (ratio 
HA/casein=1/1), previously washed with loading buffer.  
 The next steps and MALDI analysis conditions were the same as those 
already reported. The MALDI analysis of milk peptides was conducted by loading on 
the spot 1 μl of milk solution diluted 1:100 with a solution containing H2O/ACN 
(50/50). 1 μL of the DHB solution (10 mg/mL) containing  H2O/ACN/PA (49/50/1) was 
loaded on dried sample and allowed to dry.  
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Adding the suspension to skimmed pasteurized milk 
 
 Aliquots of finely ground HAS-CPP microgranules (100 and 250 mg) could 
derived from each of the above prepared samples. To avoid the immediate 
sedimentation of HAS-CPP in milk, grinding was carried out using the Ultra-Turrax 
T25 apparatus for 3min at 24,000 rpm. 100 μl (0.2% v/v) and 250 μl (0.5% v/v) of the 
suspension aliquots were added to 50 ml of raw milk. The HAS-CPP microgranules 
added to the milk were recovered by centrifugation, washed and analyzed by MALDI-
TOF to assess the residual binding capacity of the resin. 
 
13. Results and discussion 
 
 Hydroxyapatite [HA, Ca5(PO4)3OH] is a versatile biomaterial and when 
synthesized from wet-chemical precipitation reactions often forms nanoparticles with 
varying particle size and morphology, depending on the reactants and reaction 
conditions. Furthermore, the morphology, crystallite size, purity, stoichiometry, and 
structure of HA influence its bioactivity, bio-compatibility, chemical and physical 
stability, and mechanical properties, hence, its in vitro and in vivo performance after 
processing140.  
 The synthesis of HA can take place through a variety of processes. HA 
synthesis includes the sol-gel technique141, solid-state reactions at elevated 
temperatures142, and biosynthesis routes143. Among the different synthesis methods, 
the wet precipitation method for synthesizing HA was proved to be the most suitable 
to industrial application. Among the various syntheses, the wet-chemical precipitation 
reactions from Ca(OH)2 and H3PO4 were chosen for simplicity, rapidity of reaction 
and high level of repeatability.  The morphology of the HA precipitates changed 
from needlelike to nearly spherical. The aspect ratio (length-to-diameter ratio) 
decreases as the reaction temperature is increased when it is synthesized using 
Ca(OH)2 and H3PO4144,145 The crystallinity of apatites prepared at higher precipitation 
temperatures was higher than those prepared at lower precipitation temperatures (T). 
In particular T=90°C produced a higher purity and crystallinity product.146. For this 
reason, the conditions describe above were used.  
 To assess the binding capacity of the resin, three protein mixture a) isoelectric 
casein, b) milk protein and c) raw milk were loaded on HAS. These proteins were 
linked to the resin, and in situ hydrolyzed by trypsin. The spectra of the three 
preparations are compared in Figure 14.  
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Figure 14. MALDI mass spectra of CPP recovered by HAS from isoelectric casein (a), milk protein (b) 
and raw milk (c).  
 
 Although the protein mixture loaded on HAS was of different complexity, the 
CPP profile revealed by MALDI-TOF analysis was similar, indicating that binding of 
the casein fractions to HAS was the same, with respect to the sample composition 
a 
b
c
 39
and its form. This assays showed that the process was scalable for industrial 
purposes by using the most common protein source as ingredient depending on the 
specific industrial needs. Once obtained the HAS-CPP complexes on pilot scale, a 
functional food was formulated. It has been demonstrated that the addition of 2.0–5.0 
g CPP-ACP⁄l to milk increases its ability to remineralize enamel subsurface lesions147 
and the remineralizing effect of CPP-ACP in milk was dose-dependent with milk 
containing 0.2% CPP-ACP and 0.3% CPP-ACP producing an increase in mineral 
content of 81% and 164%, respectively, in comparison to the control milk148. The 
percentage of HAS-CPP was added to the functional milk. As the HAS-CPP 
suspension have greater density than milk, before addition to milk, the granules of 
HAS-CPP were finely ground to avoid their fast sedimentation. However, before 
drinking, functional milk should be shaken to homogenize the suspension.  
 Before analysis of microgranules recovered by milk, control CPP from 
skimmed pasteurized milk was carried out by MALDI analysis (Figure 15, panel a). 
This analysis disclosed the affinity of the milk proteins and peptides for the resin. The 
spectra of the HA-CPP showed casein in soluble sodium salts (not shown spectrum) 
and CPP bound HA (Figure 15, panel b).  
   
 
 
Figure 15. MALDI spectra of peptides from skimmed pasteurized milk before HAS enrichment (a) and 
after HAS enrichment (b). 
  
a  
b  
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 In the spectra of the untreated skimmed pasteurized milk, four non-
phosphorylated peptides such as β-CN (f184-204), αs1-CN (f2-22), αs2-CN (f189-207) 
and αs1-CN (f179-199) together with a number of CPP (Figure 15, panel a) was 
detected in the wider mass range 2200-4200 Da. Sample treated with HAS 
microgranules specifically captured CPP, while those non-phosphorylated 
contaminating the resin were removed by extensive washings in batch with buffer as 
detailed in the experimental procedure 1.   
 Furthermore, the HAS-CPP microgranules added to milk were recovered by 
centrifugation and bound CPP were detected by MALDI-TOF, by loading 
microgranules on the well MALDI plate (Figure 16, panel c).  
 Comparison of the MALDI spectra amongst HA-CPP before addition to milk 
(a), peptides in untreated skimmed pasteurized milk (b) and HA-CPP fixed after 
addition to milk (c) are shown  in Figure 16 (panel a-c). The microgranules of HAS-
CPP added to milk (Figure 16, panel a) were able to chelate further free CPP in milk 
(Figure 16, panel b). 
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Figure 16. MALDI spectra of comparison between HA-CPP before addition to milk (a), peptides in 
untreated skimmed pasteurized milk (b) and HA-CPP after addition to milk and after recovery by 
centrifugation (c).  
 
 The HA-CPP microgranules added to milk were able to chelate further free 
CPP of milk as demonstrated in the spectrum (Figure 16, panel c) by the increased 
signals of peptides marked in purple. The number of CPP present in skimmed 
pasteurized milk sample (Figure 16, panel b) increased the level of CPP binding 
HAS-CPP complexes after addition to milk compared to the control (Figure 16, panel 
a). This means that some C-sites of HAS yet remained accessible to phosphate 
groups while the P-sites were able to chelate metal ions. 
c 
b
a 
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 Finally, the same sensory characteristics of functional milk have been 
evaluated. Milk enriched with CPP showed the same sensory characteristics as 
starting milk, as CPP were neutralized by the calcium ions of the HAS crystals. The 
HAS-CPP complex is odourless and tasteless. 
 The HAS-CPP complex has been added to milk but it could be added to a 
wide range of products as toothpaste, toothpowder, topical gels, dental filling 
material, mouthrinse, chewing gum, lozenges, tablets, mineral drinks, nutritional 
supplements for children, confectionery, and products for dental care mouthrinse. 
 In conclusion, the preparation of a functional drink in semi-industrial settlement 
allowed to obtain a product with inexpensive raw materials and with nutraceutical 
ingredients (HAS-CPP) that could induce beneficial effects on human health 
especially for teeth.  
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14. Quantification of CPP in HAS-CPP preparation to be added to milk 
 
 To understand the amount of CPP addition in the milk, the problem of 
quantitative determination of CPP linked to HAS has been faced. 
 Matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOFMS) is used to obtain fast and accurate determination of molecular 
mass, but quantitative determinations are generally made by other techniques. While 
there have been reports of quantitative MALDI-TOFMS applications, there are many 
problems inherent to the MALDI ionization process that have restricted its 
widespread use149. These limitations primarily stem from factors as the limited 
dynamic range due to detector saturation, difficulties associated with coupling 
MALDITOFMS to on-line separation techniques as liquid chromatography and 
especially the sample/matrix heterogeneity that are believed to contribute to the large 
variability in observed signal intensities for analytes. A major issue is the non-
homogeneous distribution of the analyte in the cocrystallite. For example, especially 
non homogeneous needle-shaped crystals were observed when DHB was used as a 
matrix. This leads to the observation that, at several points of the sample, no analyte 
signals can be found whereas at other positions strong signals can be monitored 
(hot-spot formation). The varying ion response on different positions on the sample 
spots leads to poor “shot-to-shot” reproducibility and poor “point-to-point” 
repeatability and this is therefore one of the main reasons hampering quantitative 
MALDI MS150. Because of these difficulties, practical examples of quantitative 
applications of MALDI-TOFMS have been limited. Internal standards have been used 
successfully to overcome these problems.151,152. For quantification, in fact, internal 
standards are necessary to compensate for the poor shot-to-shot reproducibility 
inherent in the use of MALDI analysis. The selection of an appropriate internal 
standard (IS) for quantification is critical for the successful application of quantitative 
MALDI. There are several properties of the ideal internal standard153:1) It must be 
completely resolved from the analyte; 2) It must be chemically stable during the 
analysis; 3) It should be chemically similar to the analyte (including ionization and 
extraction efficiencies) and should not react with the analyte; 4) It should be close to 
the analyte in mass and concentration to avoid instrumental errors. Ideal internal 
standards are substances showing a high physico-chemical similarity to the analyte. 
Standards labelled with stable isotopes like 2H, 13C, 14N or 18O deliver best results in 
terms of accuracy of the quantification154. Another strategy is the use of non-isotope 
labelled internal standards155, applying structurally modified compounds. For 
example, peptides with high molecular similarity156 were successfully used as internal 
standards for the relative quantitation of peptides. Moreover, it has been reported 
that MALDI-TOF MS can be used for the quantification of proteins and other 
bioactive molecules by evaluating the ratio of the peak heights between the analyte 
and a correctly selected.internal standard157,158 .  
 In this PhD work, synthetic internal standards were used to quantify tryptic 
CPP enriched by HAS and used as ingredient for the functional milk. The synthetic 
peptide analogues which were chosen varied for a single amino acid in the peptide 
sequence to achieve a ionization efficiency equivalent to that of tryptic 
phosphopeptide in the CPP mixture.  
 Two CPP with different degree of phosphorylation as monophosphorylated 
peptide αs1-CN (f106-119) 1P (1659.8 Da) and diphosphorylated peptide, αs1-CN 
(f43-58) 2P (1926.7 Da) were chosen for the quantification. Four synthetic peptides 
were synthesized by solid-phase Fmoc synthesis without further purifications by Dr. 
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Olga Fierro (ISA CNR, Avellino) for the construction of calibration curve: the two said 
above natural peptides (PGN) and the modificated peptides analogues (PGM). The 
modified were point-mutated peptides where leucine was replaced by a glycine 
(∆m=56) in monophosphorylated peptide (PG1M) and isoleucine was replaced by a 
glycine (∆m=56) in diphosphorylated peptide (PG2M): 
 
Synthetic natural αs1-CN (f106-119) (PG1N):           VPQLEIVPNpSAEER (1659.8 Da) 
Synthetic modified αs1-CN (f106-119) (PG1M):        VPQGEIVPNpSAEER (1603.7 Da) 
Synthetic natural αs1-CN (f43-58) (PG2N):               DIGpSEpSTEDQAMEDIK (1926.7 Da) 
Synthetic modified αs1-CN (f43-58) (PG2M):            DGGpSEpSTEDQAMEDIK (1870.6 Da) 
 
 As the two natural and analogue peptides had almost identical sequences, no 
significant difference in ionization efficiency was expected when mixtures of PG1N 
and PG1M and  PG2N and PG2M were analyzed by MALDI-TOF. Measurements were 
made on the mixture containing PG1N and PG1M (Figure 17) and PG2N and PG2M 
(Figure 18) in 1:1(w/w) ratio.  
 
 
 
Figure 17. MALDI spectrum of a solution containing PG1N and PG1M in 1:1 ratio 
            
Figure 18. MALDI spectrum of a solution containing PG2N and PG2M in 1:1 ratio 
 
 It is worthy of note that, at this ratio, the peptide analogues showed different 
ionization even if the sequence varied in a single amino acid residue and 
concomitantly for the purity. This afforded different interaction with the matrix causing 
different ionization efficiency. It has experimentally been demonstrated that in order 
to have the same ionization the PG1N/PG1M ratio was 0.4/1 and PG2N/PG2M ratio was 
0.9/1 as shown in the ‘concentration ratio’ column (Table 4 and 5). Taking into 
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account these ratios, three solutions containing concentrations of PGN and PGM in 
ratios of 1:1, 0.5:1 and 0.1:1 were compared (Figure 19 and 20).  
 
 
 
 
 
Figure 19. MALDI spectra of solutions containing PG1N and PG1M in ratios of 1:1, 0.5:1 and 0.1:1 to 
detect the area of the underlying peak.   
 
 
 
  
Figure 20. MALDI spectra of solutions containing PG1N and PG1M in ratios of 1:1, 0.5:1 and 0.1:1 to 
detect the area of the underlying peak. 
 
 The peptide mixture was analysed by MALDI-TOF, operating in reflector 
mode. The spectra were recorded by acquiring about 500 shots/spectrum to 
compensate for uneven ionization within the sample spots. Laser intensity was kept 
constant during the acquisition of data points. Each data point represents the 
average of five different spectra. The calibration curve was obtained by measuring 
the area of the underlying peak of synthetic natural peptide and its corresponding 
modified counterparts. The value of each area was obtained by the summation of 
areas of the whole isotopic cluster. For each ratio, the average area of different five 
spectra was considered (Table 4 and 5). In these tables, the concentrations of 
peptides were also reported.  
 
 
 
 
 
 
 
 
1:1 0.5:1 0.1:1  
0.5:1 0.1:1  1:1
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Table 4. Measured values for the construction of the calibration curve using αs1 (106-119) 1P and its 
modified peptide form PG1N 
 
 
 
Expected 
N/M ratio 
 Peak 
AreaN  
Peak 
AreaM  
Area  
ratio
ng/ml of 
PG1N  
ng/ml of 
PG1M  
Concentration 
ratio 
1/1 263792.25 276173.54 0.96 0.4 1 0.4 
0.5/1 97657.95 194804.78 0.50 0.2 1 0.2 
0.1/1 35621.34 234596.16 0.15 0.04 1 0.04 
 
 
 
Table 5. Measured values for the construction of the calibration curve using αs1 (43-58) 2P peptide 
(PG2N) 
 
Expected 
N/M ratio 
 Peak 
AreaN  
Peak 
AreaM  
Area  
ratio 
ng/ml of 
PG2N  
ng/ml of 
PG2M  
Concentration 
ratio 
 1/1 239694.67 226015.81 1.06 0.9 1 0.9 
0.5/1 104187.91 149248.32 0.70 0.45 1 0.45 
0.1/1 25628.06 174475.81 0.15 0.09 1 0.09 
 
 
 The peak area ratio (Area PGN/Area PGM) was proportional to the measured 
concentrations of the corresponding peptides as shown by equation of the calibration 
curve (Figure 21 and 22).  
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Figure 21. Calibration curve of αs1 (43-58) 2P peptide  
 
 
 
Figure 22. Calibration curve of αs1 (43-58) 2P peptide  
 
 The combined data yielded the two linear calibration curves having the 
equation y = 0.4478x – 0.0267 for PG1N and y = 0.8674x – 0.071 for PG2N. A linear 
relationship (correlation R² = 0,9999 for PG1N and R² = 0.967 for PG2N) was observed 
between the peak area ratio and the concentration ratio of peptides.  
 The calibration curve was used to measure the amount of CPP (PG1N and 
PG2N) in a mixture containing HAS-CPP complexes to measure the amount of CPP 
added in functional milk. For this objective, known amounts of modified peptides 
were added to the phosphopeptide mixture. PG1M (0.1 ng/ml) and PG2M (1 ng/ml) 
were added to each solution containing HAS-CPP (1 mg/ml) dissolved in the 
minimum amount of acid (12 μl 5% PA) and diluited to a final volume of 1 ml of 
H2O/ACN (50/50). The MALDI spectra are shown below (Figure 23 and 24).      
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Figure 23. MALDI spectrum of HA-CPP mixture with PG1M added to the mixture for quantification 
PG1N. 
 
 
Figure 24. MALDI spectrum of HA-CPP mixture with PG2M added to the mixture for quantification 
PG2N. 
 
 From areas detected by MALDI and applying the linear equation, it is possible 
to know the amount of PG1N and PG2N peptide bound to the HAS. In 1 mg of HAS, 
there are 0.07 ng (40% of 0.18) of αs1 (106-119)1P and 1.26 ng (90% of 1.4) of αs1 
(43-58)2P. As 100 mg and 250 mg of HAS-CPP were added to the functional milk, 7 
ng and 17.5 ng of αs1 (106-119)1P and 126 ng and 315 ng of αs1 (43-58)2P were 
added to 50 ml of milk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49
15. Evaluation of the quality of used milk for CPP preparation   
 
 The third part of the PhD work has been dedicated to the study for the 
evaluation of milk quality for CPP preparation. If abnormal milk is used for the 
formulation of a functional drink, the quality of CPP preparation could substantially 
change.  
 Endogenous milk enzymes are technologically significant for the deterioration 
of milk through proteolytic modification of native casein. Many of the these enzymes 
originate from somatic cells (neutrophils, macrophages, lymphocytes and a smaller 
number of epithelial cells)159. The neutrophils, also called polymorphonuclear 
leukocytes (PMN), dominate in milk during mastitis160. This pathology is an illness 
characterized by inflammation of the mammary gland and that causes the increase in 
somatic cell counts (SCC) and in proteolytic enzyme activities. Plasmin, the active 
enzyme derived from plasminogen activation, is usually considered as the principal 
proteolytic milk enzyme. Both plasmin and plasminogen-derived activities in milk 
increase with SCC and severity of mastitic infection, due to a weakened blood–milk 
barrier, and therefore contribute to the proteolytic systems in mastitic milk161. Plasmin 
activity was found to increase more than the plasminogen derived activity and it 
suggested that the increased plasmin activity in mastitic milk was due to both 
increased influx of plasminogen from blood to milk and increased activation162. In 
bovine milk, the proteose-peptone fraction was investigated in relation to health 
status of the animals163. β-CN-5P (f1-105/7) peptides should increase in subclinical 
mastitic milk because these components are breakdown products of β-casein by 
plasmin. Indeed, these peptides actually resulted a mixture of transient intermediate 
proteolytic products, as the β-CN5P (f1-105) also occurred in control milk. Therefore, 
they were considered as inappropriate indicators of subclinical mastitis. In contrast, 
the components β-CN (f29-105/7)1P as terminal products of plasmin-like activity 
were correlated with the plasmin activity as indicators of the endogenous proteolysis 
in milk from cows with subclinical mastitis. In addition to plasmin, there are also other 
native proteinases in milk that may be secreted from somatic cells or leaked out from 
damaged somatic cells164. Proteinases, including elastase and cathepsin G, are the 
predominant enzymes associated to somatic cells of mastitic milk165 whose specificity 
towards αs1- and β-casein is well documented166,167,168. Other proteinases found in 
mastitic milk include cathepsin B and the acid protease cathepsin D169. Recently, the 
avtivity of alkaline phosphatase (ALP) in association with subclinical mastitis (SCM) 
has been evidenced. The mean activities of ALP were higher in the milk from udders 
with SCM than in the milk from healthy udders, since the blood–milk barrier is 
damaged with infection and it is possible that ALP could be transferred from blood to 
milk. In this study, results have shown that the ALP presence was consistent in the 
early diagnosis of subclinical mastitis170. The casein phosphorylation is the most 
important posttranslational modification which declines the effect of the increased 
activity of phosphatase, associated with the somatic cells. Hence, it is important to 
extend the knowledge on the phosphorylation level of casein to better understand the 
milk technological properties. According to the casein model, phosphorylation is 
important since phosphate groups are directly involved in the micelle-micelle 
interactions during coagulation and curd syneresis171 . Moreover, casein breakdown 
in mastitic milk reduces the cheese yield as casein is partially lost in whey172. 
Furthermore, from a mastitic milk, CPP with lower degree of phosphorylation were 
obtained so that the Ser(P)-Ser(P)-Ser(P)-Glu-Glu cluster  important for transporting 
minerals was altered.  
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 The objective of the first part of this work was to study the phosphorylation 
kinetic of casein, via the dephosphorylation in vitro of bovine casein to understand 
the potential of the HA-based enrichment technique.  
 In the second part, the casein and milk phosphopeptides with high level of 
SCC were studied, applying the same enrichment procedure. As model was 
assumed ovine casein isolated from the same animal with left udder with low and 
right one with higher level of SCC. Another important difference between the casein 
samples was the different ALP activity. Furthermore, the identity of the casein 
fractions and tryptic derived casein phosphopeptides with the exact number of 
phosphate group was unambiguously determined by mass spectrometry (MS). At the 
end of the study, the conclusive remark is that testing the presence of partly 
dephosphorylated caseins directly or indirectly through derived CPP is a suitable 
indicator for mastitic milk. 
 
16. Experimental procedure 3 
 
Materials 
 
Raw ovine milk was collected from local dairy farms. Milk from the left udder 
showed low SCC, instead milk from right showed high level of SCC (4.6 x106 
cells/ml). Alkaline phosphatase (Grade I, 4,000U) from calf intestine was supplied by 
Roche (Roche Diagnostics, GmbH, Mannheim, Germany). Ammonium bicarbonate 
buffer (AMBIC) was from Carlo Erba (Milan, Italy). The other material have already 
been described above. 
 
Dephosphorylation kinetic 
 
3 samples with different degree of phosphorylation of casein fractions were 
prepared.  
Sample1: Bovine casein (10 mg) was dissolved  in 100 μL 0.4% AMBIC at pH 8 and 
dephosphorylated by alkaline phosphatase (100 μg) at an enzyme/substrate ratio of 
1:100. The reaction was carried out at 37° C for 5 min. 
Samples 2,and 3: Bovine casein (10 mg) was dissolved in 100 μL 0.4% AMBIC at pH 
8 and dephosphorylated by alkaline phosphatase (200 μg) at an enzyme/substrate 
ratio of 1:50. The reaction was carried out at 37° C for 15 min (sample 2) and 24h 
(sample 3). Each solution was analysed by MALDI-TOF, loading on the spot 1μl of 
1:100 dilution with a solution containing H2O/ACN (50/50). 1 μL of the sinapinic acid 
solution (10mg/mL) containing  H2O/ACN/PA (49.9/50/0.1) was loaded on dried 
sample and allowed to dry. The MALDI and ESI-MS analysis conditions are the same 
as those already reported above.  
 The three solutions were freeze-dried with a SpeedVac concentrator system, 
before loading on the HA. The partially dephosphorylated casein solutions were 
dissolved in 80 μl buffer at pH 8.0 containing TrisHCl 50 mM, KCl 0.2 M, urea 4.5 M, 
DTT 10 mM and were loaded on 10 mg of HA. The next steps of phosphorylated 
protein enrichment and tryptic hydrolysis in situ were the same as those already 
reported. The rapid analysis of HA-phosphoprotein/CPP microgranules deposition 
was conducted for phosphoprotein/CPP enriched by HA. The microgranules were 
deposited onto the MALDI plate and covered by the SA matrix in presence of 0.1% 
TFA for proteins and by DHB solution in presence of 1% PA for CPP. 
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HA-based phosphoprotein/peptide enrichment of milk mastitic 
 
 Ovine casein (10 mg) from right udder with high level of SCC was dissolved in 
80 μl buffer at pH 8.0 containing TrisHCl 50 mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM 
and loaded on HA (10 mg), previously washed with loading buffer. The next steps of 
phosphorylated protein enrichment and tryptic hydrolysis in situ were the same as 
those already reported. The MALDI analysis conditions are the same as those 
already reported. 
 
17 Results and discussion   
17.1 Dephosphorylation kinetic 
 
 The HA enrichment technique was applied to partially dephosphorylated 
casein. The objective was to understand the affinity of the resin for a protein mixture 
with different phosphorylation degree.  
The enzyme-to-casein ratios and reaction time chosen were consistent with the 
optimum reaction kinetics.  
After 24h, all proteins were dephosphorylated and no protein remained bound 
to the resin after loading on HA. From the comparison between the MALDI spectra of 
the casein fractions before (Figure 25 and 26, panel a) and after HA enrichment 
(Figure 25 and 26, panel b), it is evident that the resin has a greater affinity for 
proteins with a higher phosphorylation degree. In fact, the more phosphorylated 
proteins (green colored phosphoprotein) (Figure 25 and 26, panel b) appeared only 
after the HA enrichement. Before enrichment, the signals of more phosphorylated 
component were suppressed by that of the less phosphorylated components. 
Moreover, αs2-CN signals significantly increased (Figure 25 and 26, panel b) allowing 
a more correct identification of CPP. 
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Figure 25. Spectra MALDI of thecasein fractions (sample 1) after partially dephosphorylation at 
enzyme/substrate ratio of 1/100 for 5min (a) before and (b) after enrichment on HA. Signals of αs2CN 
have been indicated with a colour for a better visual identification of the fractions. 
 
a 
b 
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Figure 26. MALDI spectra of casein fractions (sample 2) after partially dephosphorylation at 
enzyme/substrate ratio of 1/50 for 15min (a) before and (b) after enrichment on HA. 
 
 The identification of totally and partially phosphorylated casein fractions at 
different dephosphorylation reaction time (t=0, t=5 min and t=15 min) before and after 
casein enrichment are compared in Tables 6 and 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b 
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Table 6. Dephosphorylation kinetics before casein enrichment by HA 
 
 tAP=0 min
tAP=5 min  
AP/protein=1/100 
tAP=15 min 
AP/protein=1/50
Phosphoprotein Theoretical mass (Da)
Measured 
mass (Da)
Measured mass 
(Da) 
Measured mass 
(Da) 
k-CN 1P 19022.59 19028.54 19025.56 19026.89 
k-CN 0P 18942.59  —  18943.56 18946.89 
γ1-CN 1P 20562.01 20554.78 20514.38 20452.03 
αs1-CN 8P 23614.87 23627.56  — — 
αs1-CN 7P 23534.87 23534.56 23525.10 — 
αs1-CN 6P 23454.87   — 23444.31 — 
αs1-CN 5P 23374.87   — 23363.95 — 
αs1-CN 4P 23294.87   — 23284.31  —  
αs1-CN 3P 23214.97   — 23205.13 23206.74 
αs1-CN 2P 23134.87 — 23124.54 23126.74 
αs1-CN 1P 23054.87 — 23044.85 23052.19 
β-CN 5P 24022.39 24036.26 — — 
β-CN 4P 23942.39 24955.27 — — 
β-CN 3P 23862.39 — 23891.92 — 
β-CN 2P 23782.39 — 23811.92 — 
β-CN 1P 23702.39 — 23733.73 23700.40 
β-CN 0P 23622.39 — 23651.73 23611.37 
αs2-CN 12P 25308.48 — — — 
αs2-CN 11P 25228.46 — — — 
αs2-CN 9P 25068.46 — 25050.02 — 
αs2-CN 6P 24828.46 — 24809.74 — 
αs2-CN 4P 24668.46 — 24656.68 24661.11 
αs2-CN 3P 24588.46 — 24576.68 24590.79 
αs2-CN 2P 24508.46 — — 24510.79 
αs2-CN 1P 24428.46 — — 24430.05 
αs2-CN 0P 24348.46 — — 24353.04 
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Table 7. Dephosphorylation kinetics after casein enrichment by HA 
 
  tAP=0 min 
tAP=5 min  
AP/protein=1/100 
tAP=15 min 
AP/protein=1/50
Phosphoprotein Theoretical mass (Da)
Measured 
mass (Da)
Measured mass 
(Da) 
Measured mass 
(Da) 
k-CN 1P 19022.59 19029.57 19037.40 19038.89 
k-CN 0P 18942.59 — — — 
γ1-CN 1P 20562.01 — — — 
αs1-CN 8P 23614.87 23626.52 23620.87   
αs1-CN 7P 23534.87 23539.42 23542.28 23506.43 
αs1-CN 6P 23454.87 — 23464.34 23460.76 
αs1-CN 5P 23374.87 — 23379.45 23379.38 
αs1-CN 4P 23294.87 — 23307.89 23298.82 
αs1-CN 3P 23214.97 — — 23219.78 
αs1-CN 2P 23134.87 — — 23141.44 
αs1-CN 1P 23054.87 — — 23068.08 
β-CN 5P 24022.39 24029.94 24024.78 — 
β-CN 4P 23942.39 23951.22 23945.14 — 
β-CN 3P 23862.39 — 23859.91 23870.20 
β-CN 2P 23782.39 — 23779.39 23791.09 
β-CN 1P 23702.39 — — 23703.70 
β-CN 0P 23622.39 — — — 
αs2-CN 12P 25308.48 25292.5 — — 
αs2-CN 11P 25228.46 25210.5 25231.05 — 
αs2-CN 10P 25148.46 25133.3 25153.52 — 
αs2-CN 9P 25068.46 — 25071.60 — 
αs2-CN 8P 24988.46 — 24987.32 — 
αs2-CN 7P 24908.46 — 24903.23 24909.14 
αs2-CN 6P 24828.46 — 24823.23 24830.17 
αs2-CN 5P 24748.48 — 24743.23 24753.69 
αs2-CN 4P 24668.46 — — 24669.47 
αs2-CN 3P 24588.46 — — 24589.87 
αs2-CN 2P 24508.46 — — 24502.53 
αs2-CN 1P 24428.46 — — 24426.37 
αs2-CN 0P 24348.46 — —  —  
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 The partially dephosphorylated casein fractions bound to the HA were 
hydrolyzed, in situ, under conditions indicated in Method section. By this means, 
peptides containing the Ser(P)-Ser(P)-Ser(P)-Glu-Glu cluster sequence were 
evaluated.  
 
 
 
Figure 27. MALDI spectra of tryptic CPP hydrolyzed in situ from partially dephosphorylated casein 
bound to HA. The dephosphorylated reaction was conducted at the enzyme/substrate ratio of 1/100 
for 5min (a) and with enzyme/substrate ratio of 1/50 for 15 min (b). 
 
 Comparing the MALDI spectra (Fig. 27, panel a and b), the following 
considerations can be made: 1) totally phosphorylated peptides were still present in 
a 
b
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the mixtures after 5 and 15min of the dephosphorylation reaction but the intensity 
ratio between β-CN (f1-25)4P (3122.3 Da) and β-CN (f1-25) 3P (3042.3 Da) and 
between αs1-CN (f59-79)4P (2640.9 Da) and αs1-CN (f59-79)3P (2560.9 Da) tended 
to decrease; 2) after 5min dephosphorylation reaction, αs2-CN (f46-70) 3P (2927.8 
Da) was already detectable 3) after 15min dephosphorylation reaction the αs1-CN 
(f59-79)3P (2560.1 Da), αs2-CN (f2-21)3P (2459.4 Da), αs2-CN (f46-
70)2P (2848.7) , β-CN (f1-25)2P (2963.0 Da) and  β-CN (f1-25)1P (2883.0 Da) 
phosphopeptides were recorded. The partially phosphorylated peptides issued for 
different time of dephosphorylation (t=0, t=5 min and t=15 min) are compared in 
Table 8. 
 
 
Table 8. Dephosphorylation kinetic of in situ hydrolyzed and enriched phosphopeptides. The peptides 
of new formation at tAP=5 min are marked in green and The peptides of new formation at tAP=15 min 
are marked in blue.  
 
 
  
tAP=0 min
tAP=5 min  
ratio=1/100 
tAP=15 min 
ratio=1/50 
Monophospho 
peptide  
Theoretical 
mass (Da) 
Measured 
mass (Da)
Measured 
mass (Da) 
Measured 
mass (Da) 
αs1(f106-119)1P 1659.8 1661.6 1660.9 1660.2 
αs1(f104-119)1P 1952.0 1952.3 1952.8 1951.6 
β(f33-48)1P 2060.8 2062.8 2061.7 2061,3 
αs1(f103-119)1P 2080.4 2079.4 2081.6 2078.3 
β(1-25)1P 2883.0  — —  2883.9 
Diphosphopeptide Theoretical mass (Da) 
Measured 
mass (Da)
Measured 
mass (Da) 
Measured 
mass (Da) 
αs2(f126-136)2P 1410.5 1411.0 1411.9 1411.4 
αs2(f126-137)2P 1538.6 1540.3 1540.2 1539.7 
αs1(f43-58)2P 1926.1 1928.3 1927.7 1927.1 
αs1(f43-58)1P 1846.7 1848.2 1847.8 1847.1 
αs2(f2-21)2P 2459.4 — — 2459.6 
αs1(f37-58)2P 2598.1 2598.1 2600.5 2595.8 
αs2(f46-70)2P 2848.7 —  —  2849.8 
αs1(f35-58)2P 2855.2 2855.3 2855.6 2852.9 
β(f1-25)2P 2963.0  — — 2963.7 
Triphosphopeptide Theoretical mass (Da) 
Measured 
mass (Da)
Measured 
mass (Da) 
Measured 
mass (Da) 
αs2(f2-21)3P 2539.4 2538.6 2539.4 2540.0 
αs1(f59-79)3P 2560.1 — — 2559.6 
αs1(f37-58)3P 2678.1 2677.8 2677.5 2676.7 
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β(f2-25)3P 2886.2 2885.9 2885.1 2885.4 
αs2(f46-70)3P 2928.0  — 2927.9 2927.7 
αs1(f35-58)3P 2935.2 2935,0 2933.9 2932.6 
β(f1-25)3P 3042.3 3043.8 3044.0 3043.2 
Tetraphosphopeptide Theoretical mass (Da) 
Measured 
mass (Da)
Measured 
mass (Da) 
Measured 
mass (Da) 
αs2(f2-21)4P 2618.9 2619.2 2619.9 —  
αs1(f59-79)4P pyroQ 2623.9  — 2621.0 2621.4 
αs1(f59-79)4P 2640.9 2640.7 2640.5 2639.4 
β(f2-25)4P 2966.2 2965.9 2965.0   
αs2(f46-70)4P 3007.9 3007.2 3006.8 3005.8 
β(f1-25)4P 3122.3 3122.1 3122.1 3121.0 
Pentaphosphopeptide Theoretical mass (Da) 
Measured 
mass (Da)
Measured 
mass (Da) 
Measured 
mass (Da) 
αs1(f59-79)5P pyroQ 2703.9 2703.7 2703.3 2701.9 
αs1(f59-79)5P 2720.9 2720.7 2720.4 2719.0 
αs2(f46-70)5P 3088.0 3086.7 3086.8 3085.0 
 
17.2. Analysis of proteins and CPP occurring in mastitic milk 
 
 The enrichment of mixtures dephosphorylated in vitro has confirmed the ability 
of the resin to bind phosphproteins and CPP with different degrees of 
phosphorylation. At this point, to evaluate the milk quality, our method for the 
phosphoprotein/phosphopeptide enrichment was tested on mastitic casein. In order 
to examine whether the phosphorylated proteins were enriched by HA, MALDI 
analysis was carried out on the casein sample before and after resin treatment 
(Figure 28)   
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Figure 28. MALDI spectra of casein sample before (a) and after (b) resin treatment in 
the mass range of 10-13 kDa. 
 
 The partial MALDI-TOF spectrum of the original casein sample (Figure 28, 
panel a) was compared to the same sample after the enrichment cycle by HA (Figure 
28, panel b). Original casein sample signals could be assigned to γ2-, γ3-CN, and β-
CN (f98-207). These non-phosphorylated plasmin-mediated peptides of β-CN were 
washed out when native casein sample was treated with HA. HA-treated samples did 
not contain these peptides consistently with the function of HAP in capturing 
phosphopeptides. In contrast, HA allowed phosphoproteins/phosphopeptides be 
enriched from high SCC casein as clearly shown in Figure 28, panel b. Here, in the 
partial view of the MALDI spectra, the m/z 10-13 kDa range contained a series of 
phosphopeptides with various degree of phosphorylation. In particular, together with 
the intact β-CN (not shown), the derived peptides β-CN (f1-97) (6P÷2P) and β-CN 
(f1-105) (6P÷2P) occurred. The signals of the peptide β-CN (f1-107) formed 
simultaneously with the β-CN (f1-105) counterpart were slightly detectable as β-CN 
(f1-107) (6P÷4P). The β-CN (f29-105/7)1P fragments considered by Le Roux Y. et 
al.163 as possible indicators of the endogenous proteolysis in milk from cows with 
subclinical mastitis were not found perhaps because of the dephosphorylation 
activity. It must be remembered that unphosphorylated fragments didn’t bind to the 
a  
b  
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HA. In contrast, the new fragment β-CN (f1-97) was released when the plasmin 
activity increased in mastitic milks. Consistently, the presence of the partly 
dephosphorylated fragments is connected to the higher ALP activity of mastitic milk. 
The casein derived from high SCC milk was also analysed using LC-ESI-MS to 
confirm the identity of proteins and phosphopeptides of mastitic milk. Four 
phosphorylated β-CN (6P÷3P) were detected in high SCC milk instead of the two, i.e. 
β-CN 6P and 5P occurring in control milk. Four phosphorylated αs1-CN (10P÷7P) 
were detected in high SCC instead of the two, i.e. αs1-CN 10P and 9P of control milk. 
In contrast,  αs1-CN (f141-148) (10P÷8P) and αs1-CN (Gln78) (10÷8P) deleted forms 
occurred at similar degree of phosphorylation as shown in Table 9. Moreover, we 
recorded that αs1-CN (f141-148) was the prominent internally deleted form 
consistently with that occurs in milk from healthy animal for which (110-117) form was 
found. This is in agreement with the previous results173. αs2-CN shows the highest 
number of possible phosphorylation sites compared to the other casein fractions and 
naturally occurs under two molecular species both plasmin-sensitive substrates, a 
major full-length, and an internal 9-residue domain  deleted. Both proteins show the 
same phosphorylation degree (Table 9).  
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Table 9. Identification of casein fractions in mastitic ovine milk obtained by HA enrichment and ESI-
MS analysis 
 
Measured 
molecular mass 
(Da) 
Calculated 
molecular mass 
(Da) 
Protein 
αs2-Casein  
25623.09± 4.7 25621.71 αs2(1-208)12P 
25542.38± 1.2 25541.73 αs2(1-208)11P 
25466.38± 6.2 25461.75 αs2(1-208)10P 
25378.64± 3.6 25381.77 αs2(1-208)9P 
25304.80± 5.0 25301.79 αs2(1-208)8P 
25224.71± 3.9 25221.81 αs2(1-208)7P 
      
24546.7±0.8 24546.6 αs2(1-208)-(34-42)11P 
24466.1±0.5 24466.6 αs2(1-208)-(34-42)10P 
24386.2±0.8 24386.6 αs2(1-208)-(34-42)9P 
24305.5±0.3 24306.7 αs2(1-208)-(34-42)8P 
24225.9.7±0.1 24226.7 αs2(1-208)-(34-42)7P 
αs1-Casein 
23564.2± 3.0 23561.6 αs1(1-199)10P  
23481.3± 0.8 23481.7 αs1(1-199)9P 
23400.7± 1.8 23401.7 αs1(1-199)8P 
23323.2±2.8 23321.7 αs1(1-199)7P 
      
23435.0±0.8 23433.5 αs1(1-199)-(Gln78) 10P 
23354.7±0.8 23353.5 αs1(1-199) -(Gln78) 9P 
23275.4±0.4 23273.6 αs1(1-199)-(Gln78) 8P 
      
22546.70±3.5 22549.5 αs1(1-199)-(141-148)10P 
22466.53±3.1 22469.5 αs1(1-199)-(141-148)9P 
22386.15±3.5 22389.5 αs1(1-199)-(141-148)8P 
22306.20±3.5 22309.5 αs1(1-199)-(140-148)7P 
β-Casein 
23830.98±1.1 23831.14 β(1-207)6P 
23747.04±4.7 23751.16 β(1-207)5P 
23667.23±3.7 23671.18 β(1-207)4P 
23587.32±4.2 23591.19 β(1-207)3P 
 
 
 The ESI-MS analysis allowed the identification of a wide variety of 
phosphorylated peptides of different size and wide phosphorylation degree derived 
from the intense enzymatic degradation associated with high SCC (Table 10). 
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Table 10. Identification of peptides in mastitic milk obtained by HA enrichment and LC-ESI-MS 
analysis. N-terminal and C-terminal cleavage sites are highlighted. The degree as well as maximum 
degree of phosphorylation are compared. 
 
Fragment N-terminal cleavage site 
C-terminal 
cleavage site
Degrees of 
Phosphorylation 
 Maximum 
degree of 
phosphorylation 
β-Casein (1-207) 
β(f1-29) — Lys29-Ile30 5P, 4P, 3P, 2P 5P 
β(f29-60) Lys28-Lys29 Tyr60-Pro61 1P 1P 
β(f30-60) Lys29-Ile30 Tyr60-Pro61 1P 1P 
β(f1-97) — Lys97-Val98 6P, 5P, 4P, 3P, 2P 6P 
β(f1-105) — Lys105-His106 6P, 5P, 4P, 3P, 2P 6P 
β(f1-107) — Lys107-Glu108 6P, 5P, 4P 6P 
αs2-Casein (1-208) 
αs2(f1-25) — Lys25-Asn26 4P, 3P 4P 
αs2(f36-69) Lys35-Leu36 Glu69-Val70 4P, 3P, 2P 4P 
αs2(f36-71) Lys35-Leu36 Lys71-Ile72 3P, 2P 4P 
αs2(f36-77) Lys35-Leu36 Lys77-His78 3P, 2P 4P 
αs2(f1-53) — Tyr53-Ser54 4P, 3P, 2P, 1P 4P 
αs2(f54-115) Tyr53-Ser54 Arg115-Asn116 4P,3P 4P 
αs2(f54-204) Tyr53-Ser54 Tyr204-Val205 7P, 6P, 5P, 4P 7P 
αs2(f54-208) Tyr53-Ser54 — 7P, 6P, 5P, 4P 7P 
αs2(f116-204) Arg115-Asn116 Tyr204-Val205 3P, 2P, 1P 3P 
αs2(f116-208) Arg115-Asn116 — 3P, 2P, 1P 3P 
αs2(f115-151) Lys114-Arg115 Lys151-Thr152 3P, 2P 3P 
αs1-Casein (1-199) 
αs1(f4-58) Lys3-His4 Lys58-Gln59 3P, 2P, 1P 3P 
αs1(f1-60) — Met60-Lys61 3P, 2P, 1P 3P 
αs1(f2-60) Arg1-Pro2 Met60-Lys61 3P, 2P, 1P 3P 
αs1(f61-174) Met60-Lys61 Thr174-Asp175 6P, 5P, 4P 7P 
αs1(f62-174) Lys61-Ala62 Thr174-Asp176 6P, 5P, 4P 7P 
αs1(f62-199) Lys61-Ala62 — 7P, 6P 7P 
αs1(f62-90) Lys61-Ala62 Arg90-Tyr91 4P, 3P, 2P 6P 
αs1(f43-102) Lys42-Asp43 Lys102-Lys103  5P, 4P, 3P, 2P 8P 
αs1(f43-103) Lys42-Asp43 Lys103-Tyr104  5P, 4P, 3P, 2P 8P 
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 The specific cleavage of Lys-X and Arg-X at C-terminal position was clearly 
due to the increased activity of plasmin. In complement with other bonds, Tyr-X 
cleavage was caused by cathepsin G. All peptides showed a wide phosphorylation 
range, suggesting that proteolytic cleveage occurred concurrently with the intense 
dephosphorylation enzyme correlated with increased phosphatase activity.  
 Additionally, the tryptic in situ hydrolysis of mastitic casein bound to HA 
provided additional information about the milk quality to be used as nutraceutical. 
The identification of these CPP could represent easier indicators about the nature of 
milk, mastitic or not-mastitic. As dephosphorylation produces a characteristic mass 
decrease of 80 Da or multiple of 80 Da, CPP with this mass variation confirmed the 
phosphatase activity. This procedure was found very effective and actually 
represents one of the most powerful tool for the identification of parent 
phosphorylated proteins. The partial view of the MALDI spectra in two mass ranges 
taken by direct analysis of the crystallized matrix containing HA and phosphoric acid 
is shown in Figure 29 (panel a and b). 
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Figure 29. MALDI spectrum of tryptic CPP HA-enriched from mastitic milk in different mass range: 1-
2.9 kDa (a) and 2.8-3.7 kDa (b). Adducts of CPP with K+ are encircled in green. 
 
 
All the tryptic phosphopeptides identified in the HA-enriched fraction are listed 
in Table 11. 
 
 
a  
b
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Table 11. Tryptic CPP enriched from mastitic ovine milk 
 
User 
mass 
(Da) 
DB 
mass 
(Da) 
Peptide Position Modifications 
β-Casein 
3542.83 3544.27 REQEELNVVGETVESLSSSE ESITHINK/(K) β-CN (f1-28) 
PHOS PHOS 
PHOS PHOS 
PHOS   
3462.83 3465.28 REQEELNVVGETVESLSSSE ESITHINK/(K) β-CN (f1-28) 
PHOS PHOS 
PHOS PHOS  
3385.43 3385.30 REQEELNVVGETVESLSSSE ESITHINK/(K) β-CN (f1-28) 
PHOS PHOS 
PHOS  
3306.42 3304.33 REQEELNVVGETVESLSSSE ESITHINK/(K) β-CN (f1-28) PHOS PHOS  
3226.04 3225.34 REQEELNVVGETVESLSSSE ESITHINK/(K) β-CN (f1-28) PHOS  
2062.01 2062.99 (K)/FQSEEQQQTEDELQDK/(I) β-CN (f33-48) PHOS  
αs1-Casein 
2905.49 2905.78 (K)/ENINELSKDIGSESIEDQAM EDAK/(Q) αs1-CN (f35-58) 
PHOS PHOS 
PHOS  
2825.08 2826.79 (K)/ENINELSKDIGSESIEDQAM EDAK/(Q) αs1-CN (f35-58) PHOS PHOS  
1898.54 1898.78 (K)/DIGSESIEDQAMEDAK/(Q) αs1-CN (f43-58) PHOS PHOS  
1818.40 1798.92 (K)/DIGSESIEDQAMEDAK/(Q) αs1-CN (f43-58) PHOS 
2158.69 2155.97 K)/DIGSESIEDQAMEDAKQM/(K) αs1-CN (f43-60)2P 
PHOS PHOS 
Aspecific 
cleavage 
1239.82 1238.50 (K)/ SAEQLHSMK /(E) αs1-CN (f115-124) PHOS  
2287.34 2287.75 (K)/AGSSSSSEEIVPNSAEQK/(Y) αs1 CN (f62-79) 
PHOS PHOS 
PHOS PHOS 
PHOS PHOS  
2208.60 2207.77 (K)/AGSSSSSEEIVPNSAEQK/(Y) αs1-CN (f62-79) 
PHOS PHOS 
PHOS PHOS 
PHOS  
2127.85 2127.79 (K)/AGSSSSSEEIVPNSAEQK/(Y) αs1-CN (f62-79) PHOS PHOS PHOS PHOS  
αs2-Casein 
3187.93 3192.10 (K)/HKMEHVSSSEEPINISQEIY KQEK/(N) α s2-CN (f2-25) 
PHOS PHOS 
PHOS PHOS  
3105.60 3111.13 (K)/HKMEHVSSSEEPINISQEIY KQEK/(N) α s2-CN (f2-25) 
PHOS PHOS 
PHOS  
3031.89 3032.14 (K)/HKMEHVSSSEEPINISQEIY KQEK/(N) α s2-CN (f2-25) PHOS PHOS  
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2951.98 2952.16 (K)/HKMEHVSSSEEPINISQEIY KQEK/(N) αs2-CN (f2-25) PHOS  
2934.22 2934.85 KHKMEHVSSSEEPINISQEI YK/(Q) αs2-CN (f1-22) 
PHOS PHOS 
PHOS PHOS  
2854.40 2854.87 KHKMEHVSSSEEPINISQEI YK/(Q) αs2-CN (f1-22) 
PHOS PHOS 
PHOS  
2775.72 2774.89 KHKMEHVSSSEEPINISQEI YK/(Q) α s2-CN (f1-22) PHOS PHOS  
2693.81 2694.91 KHKMEHVSSSEEPINISQEI YK/(Q) α s2-CN (f1-22) PHOS  
2540.45 2541.36 (K)/MEHVSSSEEPINISQEIYK/(Q) αs2-CN (f4-22) PHOS PHOS PHOS PHOS  
2461.48 2461.38 (K)/MEHVSSSEEPINISQEIYK/(Q) α s2-CN (f4-22) PHOS PHOS PHOS  
1540.62 1540.41 (R)/EQLSTSEENSKK/(T) αs2-CN (f126-137) PHOS PHOS  
1412.48 1412.24 (R)/EQLSTSEENSK/(K) αs2-CN (f126-136) PHOS PHOS 
αs2-Casein aspecific cleavage of tryptic CPP 
2806.00 2806.68 KHKMEHVSSSEEPINISQEI Y(K) 
αs2-CN (f1-21)    C-termin. Tyr21-
Lys22 
PHOS PHOS 
PHOS PHOS  
2677.00 2678.50 (K)HKMEHVSSSEEPINISQEIY(K) 
αs2-CN (f2-21)    C-termin. Tyr21-
Lys22 
PHOS PHOS 
PHOS PHOS 
2412.00 2413.19 (K)MEHVSSSEEPINISQEIY(K) 
αs2-CN (f4-21)    C-termin. Tyr21-
Lys22 
PHOS PHOS 
PHOS PHOS 
2254.42 2253.97 (Y)SIRSSSEESAEVAPEEVK/(I) 
αs2-CN (f54-71)   N-termin. Tyr53-
Ser54 
PHOS PHOS 
PHOS PHOS   
2174.12 2174.99 (Y)SIRSSSEESAEVAPEEVK/(I) 
αs2-CN (f54-71)   N-termin. Tyr53-
Ser54 
PHOS PHOS 
PHOS  
 
 It is possible to note the absence of non-phosphorylated peptides confirming 
the specificity of the HA-based procedure while the presence of partially 
dephosphorylated forms validated casein from high SCC.  
 From native β-casein, five partly dephosphorylated CPP species were 
identified, corresponding to loss of 1, 2, 3, 4 and 5 phosphate groups. The presence 
of β-CN (f1-28) (5P÷1P) is an additional indicator to the previous finding. A lower 
phosphorylation degree (6P÷3P) was observed before trypric hydrolysis (Table 9). 
This means the partial dephosphorylation of β-casein in the presence of anomalous 
SSC.  
 From the native αs1-casein, tryptic hydrolysis produced αs1-CN (f62-79)6P 
(6P÷4P) and CPP as αs1-CN (f43-60)2P due to aspecific cleavage. 
 From αs2-casein, αs2-CN (f2-25)4P (4P÷2P) and aspecific αs2-CN (f54-71)4P 
(4P÷3P) were released. Three CPP having different N-terminal extension, i.e. 1-22, 
4-22 and 2-25, raise from αs2CN (Table 11). All CPP containing the cluster Ser(P)-
Ser(P)-Ser(P)-Glu-Glu, essential to bind minerals, showed a wide degree of 
phosphorylation due to the loss of phosphate groups. 
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 In conclusion, high plasmin (or other proteases) activity associated with high 
cell count, and especially alkaline phosphatase activity may represent mastitis 
indicator.  The enrichment by HA of phosphoproteins and CPP is fundamental for 
evaluating milk quality. 
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18. Use of CPP as process markers 
 
 CPP can also represent process markers. Proteolysis and casein and 
phosphopeptide dephosphorylation is of utmost interest in the cheese ripening. We 
considered Grana Padano (GP) cheese where the biochemical changes which occur 
during ripening are caused by the synergistic action of a variety of enzymes, such as 
chymosin, indigenous milk enzyme proteinase, starter bacteria enzymes, and 
secondary microorganisms enzymes174. Then, it has been suggested that acid 
phosphatases from both milk and lactic acid bacteria contribute to dephosphorylation 
of phosphopeptides in cheese, which are produced from casein by enzymatic activity 
during cheese ripening175. In cheese made from pasteurized milk, indigenous acid 
phosphatase or bacterial phosphatases are probably responsible for 
dephosphorylation of caseins, but in raw milk cheese, e.g. Parmigiano Reggiano or 
Grana Padano, ALP may play an important role176. Hence, in a cheese made from 
raw milk, the enzymatic activity is more intense than that occurring in a cheese made 
from pasteurized milk. Pasteurization, in fact, inactivates several enzymes in milk, 
including lipase and alkaline phosphatase. Lack of alkaline phosphatase activity 
indicates that the milk has been properly pasteurized. As Grana Padano is a D.O.P. 
cheese and its Production Disciplinary states that it must be produced with raw milk, 
it is important to have a technique for controlling the use of raw milk. It has been 
demonstrated that a centripetal temperature gradient and a consequent gradient of 
alkaline phosphatase inactivation between the outer part and the core of GP cheese 
takes place during moulding. The traditional cheesemaking technology also includes 
milk clotting at 32° C, curd cooking up to 55° C, and cheese moulding at room 
temperature for 48 h. It has been able to note that the temperature decreases rapidly 
to 35-40° C at the surface, but because of the slow heat-transfer within the cheese, 
the core remains at 52-56 °C for 8-10 h. Such condition promotes the formation of a 
centripetal gradient of ALP inactivation which remains unmodified in moulded forms 
at room temperature throughout ripening177. The outside of the Grana contain levels 
of residual phosphatase about 10-100 times higher than the core of cheese. 
Moreover, the significant heat load on the inner zones of the cheese together with the 
low pH value may reduce the activity of other indigenous and heat-sensitive 
enzymes, like acid protease178. Also an increased proteolytic activity was observed 
mainly in the outer zone of cheese. More free amino acids (FAA) were detected in 
the outer parts of GP cheese179 just caused by the higher enzyme activities than in 
the cheese core. The peptide degradation involves firstly dephosphorylation of the 
SerP N-terminal and then release of Ser by aminopeptidases177. This mechanism 
was confirmed by the extremely low levels of SerP found in the free amino acid (FAA) 
containing fraction of GP whereas free Ser accumulated as a consequence of the 
simultaneous presence of both active phosphatase and aminopeptidase. As well 
known, constitutive alkaline phosphatase is inactivated by milk pasteurization which 
can affect splitting of SerP during cheese ripening: If SerP wasn’t dephosphorylated 
by residual phosphatase, free Ser cannot be released by the bacterial 
aminopeptidase activity. Hence, milk pasteurization originates  an equal distribution 
of FAA between the outer and the core part of the ripened cheese form. In fact, no 
free Ser gradient depending on the unequal activity of ALP within the cheese was 
observed but FAA content was depressed in comparison to control raw-milk 
cheese177 together with longer size CPP.  
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 In conclusion, the detection of a different peptide profile associated to the 
thermal gradient can be diagnostic for the use of raw milk as stated by the Decree of 
the Regulatory Production.  
19. Experimental procedure 4 
 
Materials 
 
 0.1N Hydrochloric acid solution was Carlo Erba. 3 samples of Grana Padano 
cheese, at 15 months ripening, were supplied from GranBiraghi factory obtained 
according to the traditional cheesemaking technology. For the cheese samples, a 
cylindric portion with 5cm diameter from the round side near the outer layer and from 
the core of the cheese was recovered. Each portion was grated to obtain an uniform 
sample. The other materials have been already reported. 
 
Preparation of pH 4.6-soluble fraction of cheese 
 
 Finely grated cheese (10 mg) was suspended in 45 mL of 0.1 N HCl. The 
suspension was homogenized for 1 min by an Ultra Turrax T50 and then centrifuged 
at 4,000 rpm for 30 min at 4° C. The resulting supernatant solution was freeze dried 
(Lyolab A, LSL Secfroid, Aclens, Switzerland). 
 
HA-based CPP enrichment of the pH 4.6 soluble fraction 
 
 Lyophilized soluble fraction (10 mg) was dissolved in 80 μl buffer at pH 8.0 
containing TrisHCl 50 mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM and loaded on HA 
(10mg), previously washed with loading buffer. The next steps of phosphorylated 
protein enrichment and tryptic hydrolysis in situ were the same as those already 
reported above.  
 
LC/MS Analysis 
 
 The LC-MS analysis was carried out under the conditions above reported. The 
only difference was that, instead of TFA, formic acid (FA) was used in the elution 
buffer to reduce signal suppression. 
 
20. Results and discussion 
 
 After enrichment by HA of the pH 4.6-soluble fraction of the GP inner and 
outer part, a lot of phospopeptides bound to HA, while nonphosphorylated 
compounds were washed out with buffers. From the analysis of recovered CPP, it is 
possible to note that, during cheese ripening, several CPP derived by a intense 
enzymatic hydrolysis were present in the core and the inner part of the ripened 
cheese (Tables 12 and 13). All peptides had in common the N-terminal or C-terminal 
residues. Plasmin appeared to be the main responsible enzyme for casein 
degradation during hard cheese ripening. β-Casein was extensively degraded by this 
enzyme with the concomitant formation of plasmin-derived peptides as β-CN (f1-28), 
β-CN (f1-29), β-CN (f1-32), found only in the inner part of GP (Table 12). 
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Table 12. Identification of CPP by LC-ESI-MS from the inner part of a 15-month-old cheese. 
 
Measured 
mass (Da)  
(MH+) 
Measured 
mass (Da)  
(MH2+) 
Measured 
mass (Da)  
(MH3+) 
Measured 
mass (Da) 
(MH4+) 
Amino acid sequence CPP identification 
β-casein 
1348.4 674.7   
  
                      LpSpSpSEESITR β-CN (f16-25)3P 
1435.4 718.2 479.1                   pSLpSpSpSEESITR β-CN (f15-25)3P 
1591.1 796.1 531.0                          pSpSpSEESITRINK β-CN (f17-28)4P 
1644.6 822.8 548.9                 EpSLpSpSpSEESITR β-CN(f14-25)4P 
1704.1 852.6 568.7                        LpSpSpSEESITRINK β-CN (f16-28)3P 
1743.4 872.2 581.8               VEpSLpSpSpSEESITR β-CN (f13-25)4P 
1790.6 895.8 597.5                    pSLpSpSpSEESITRINK β-CNf(f15-28)3P 
1857.1 929.1 619.7              IVEpSLpSpSpSEESITR β-CN(f12-25)4P 
1870.0 935.5 624.0                    pSLpSpSpSEESITRINK β-CN (f15-28)4P 
1871.0 936.0 624.3                 EpSLpSpSpSEESITRIN β-CN (f14-27)4P 
1999.0 1000.0 667.0                 EpSLpSpSpSEESITRINK β-CN (f14-28)4P 
2098.0 1049.5 700.0               VEpSLpSpSpSEESITRINK β-CN(f13-28)4P 
2211.5 1106.3 737.8              IVEpSLpSpSpSEESITRINK β-CN (f12-28)4P 
2341.0 1171.0 781.0           EIVEpSLpSpSpSEESITRINK β-CN (f11-28)4P 
2594.2 1297.6 865.4   VPGEIVEpSLpSpSpSEESITRINK β-CN (f8-28)4P 
2708.8 1354.9 903.6 678.0 NVPGEIVEpSLpSpSpSEESITRINK β-CN (f7-28)4P 
2967.0 1484.0 989.7 742.5    ELEEL                                  
NVPGEIVEpSLpSpSpSEESITR 
β-CN (f2-25)4P 
3079.0 1540.0 1027.0 770.5         EEL                                  
NVPGEIVEpSLpSpSpSEESITRINK 
β-CN (f4-28)4P 
3123.5 1562.3 1041.8 781.6  RELEEL             
NVPGEIVEpSLpSpSpSE ESITR 
β-CN (f1-25)4P 
3193.0 
  
1065.0 799.0       LEEL   
NVPGEIVEpSLpSpSpSEESITR INK 
β-CN (f3-28)4P 
3322.0 1108.0 831.3    ELEEL  
NVPGEIVEpSLpSpSpSEESITR INK 
β-CN (f2-28)4P 
3450.0 1150.7 863.3    ELEEL 
NVPGEIVEpSLpSpSpSEESITRINKK 
β-CN (f2-29)4P 
3478.6 1160.2 870.4 RELEEL  
NVPGEIVEpSLpSpSpSEESITRINK 
β-CN (f1-28)4P 
3607.0 1203.0 902.5 RELEEL 
NVPGEIVEpSLpSpSpSEESITRINKK 
β-CN (f1-29)4P 
3978.0 1326.7 995.3 
RELEEL 
NVPGEIVEpSLpSpSpSEESITRINKK 
IEK 
β-CN (f1-32)4P 
αs1-casein 
1314.2 657.5   
  
                IpSpSpSEEIVPN αs1-CN (f65-74)3P 
1401.4 701.2 467.8             pSIpSpSpSEEIVPN αs1-CN (f64-74)3P 
1481.2 741.1 494.4             pSIpSpSpSEEIVPN αs1-CN (f64-74)4P 
1610.6 805.8 537.5           EpSIpSpSpSEEIVPN αs1-CN (f63-74)4P 
1681.4 841.2 561.1         AEpSIpSpSpSEEIVPN αs1-CN (f62-74)4P 
1810.6 905.8 604.2       EAEpSIpSpSpSEEIVPN αs1-CN(f61-74)4P 
1965.3 983.2 655.8                   IpSpSpSEEIVPNpSVEQK αs1-CN (f65-79)4P 
2132.0 1066.5 711.3   pSIpSpSpSEEIVPNpSVEQK αs1-CN (f64-79)5P 
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2261.0 1131.0 754.3 EpSIpSpSpSEEIVPNpSVEQK αs1-CN(f63-79)5P 
2333.5 1167.3 778.5 AEpSIpSpSpSEEIVPNpSVEQK αs1-CN (f62-79)5P 
2462.0 1231.5 821.3 EAEpSIpSpSpSEEIVPNpSVEQK αs1-CN(f61-79)5P 
αs2-casein 
1515.4 758.2 505.8 
  
                    pSpSpSEESIIpSQE αs2-CN (f8-18)4P 
1614.4 807.7 538.8                   VpSpSpSEESIIpSQE αs2-CN (f7-18)4P 
2006.6 1003.8 669.5 VpSpSpSEESIIpSQETYK αs2-CNf(f7-21)4P 
 
 In the outer parts of cheese, the higher intense enzymatic hydrolysis with 
respect to the core caused the degradation of these precursors and their 
disappearance (Table 13). 
 
Figure 13. Identification of CPP by LC-ESI-MS from the outer portion of a 15-month-old cheese 
sample. 
 
Measured 
mass (Da) 
(MH+) 
Measured 
mass (Da)  
(MH2+) 
Measured 
mass (Da)  
(MH3+) 
Measured 
mass (Da) 
(MH4+) 
Amino acid sequence CPP identification 
β-casein 
1192.2 596.8   
  
               LpSpSpSEESIT β-CN (f16-24)3P 
1348.4 674.8 450.2                   LpSpSpSEESITR β-CN (f16-25)3P 
1359.2 680.2               SLpSpSpSEESIT β-CN (f15-24)4P 
1435.4 718.0 479.0                SLpSpSpSEESITR β-CN (f15-25)3P 
1703.8 852.4 568.6                        LpSpSpSEESITRINK β-CN (f16-28)3P 
1742.0 872.2 582.0         VEpSLpSpSpSEESITR β-CN (f13-25)4P 
1870.6 935.8 624.0                 pSLpSpSpSEESITRINK β-CN (f15-28)4P 
1871.0 936.0 624.4               EpSLpSpSpSEESITRIN β-CN (f14-27)4P 
1999.0 1000.4 667.4                 EpSLpSpSpSEESITRINK β-CN (f14-28)4P 
2211.8 1106.6 738.0 553.8              IVEpSLpSpSpSEESITRINK β-CN (f12-28)4P 
2341.6 1171.3 781.2             EIVEpSLpSpSpSEESITRINK β-CN (f11-28)4P 
2708.8   903.6 677.8 NVPGEIVEpSLpSpSpSEESITRINK β-CN (f7-28)4P 
αs1-casein 
1314.2 657.8   
  
                IpSpSpSEEIVPN αs1-CN (f65-74)3P 
1320.4 660.8            EpSIpSpSpSEEIV αs1CN (f63-72)3P 
1401.4 701.2 468.0             pSIpSpSpSEEIVPN αs1-CN (f64-74)3P 
1481.4 741.2 494.4             pSIpSpSpSEEIVPN αs1-CN (f64-74)4P 
1610.6 805.5 537.3           EpSIpSpSpSEEIVPN αs1-CN (f63-74)4P 
1681.4 841.0 561.0         AEpSIpSpSpSEEIVPN αs1-CN (f62-74)4P 
1965.4 983.4 656.0   IpSpSpSEEIVPNpSVEQK αs1-CN (f65-79)4P 
2132.4 1067.0 711.6   pSIpSpSpSEEIVPNpSVEQK αs1-CN (f64-79)5P 
2333.0 1166.8 778.4 AEpSIpSpSpSEEIVPNpSVEQK αs1-CN (f62-79)5P 
αs2-casein 
1515.4 758.2 505.6 
  
  pSpSpSEESIIpSQE αs2-CN (f8-18)4P 
1614.4 807.8 538.8 VpSpSpSEESIIpSQE αs2-CN (f7-18)4P 
 
 
 Plasmin hydrolysed αs1-casein producing the αs1-CN (f61-79) peptide further 
attacked at the Met60-Glu61 peptide bond, originated by action of an unknown 
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endopeptidase. The consequent formation of the three peptides such as αs1-CN(f1-
60)2P, αs1-CN (f23-60)2P and αs1-CN (f61-79) 5P182 was recorded. 
 Plasmin hydrolysed αs2-casein producing the αs2-CN (f1-21) fragment. Then, 
several shorter CPP were released from this precursor through the combined action 
of proteases and phosphatases; each peptide was devoid of one or more residues at 
the N- and/or C-terminus (Table 12 and 13). Following the specific cleveage of 
plasmin-derived CPP, it is possible to deduce the activity of general and specific 
aminopeptidases (which release the N-terminal amino acid from oligopeptides), 
phosphatase and carboxypeptidases A and B (which release the C-terminal amino 
acid from oligopeptides). In particular, the synergistic activity of phosphatase and 
aminopeptidases allows to obtain shorter CPP with cleavage in the cluster Ser(P)-
Ser(P)-Ser(P)-Glu-Glu, otherwise resistant to any enzymatic activity180. As already 
mentioned, the presence of CPP such as αs1-CN (f65-74)3P, αs1-CN (f65-79)4P and 
β-CN (f16-25)3P is possibly due to the formation of dephosphorylated intermediate 
peptides such as αs1-CN (f64-74)3P and β-CN (f15-25)3P. This synergistic enzyme 
activity was also present in the inner part of GP. Here, the residual activity of 
phosphatases was very low as demonstrated by the higher number of CCPs in the 
GP core. This was sign of a lower enzyme activity than in the outer part of cheese 
form. All larger CPP such as β-CN (f2-25)4P, β-CN (f4-28)4P, β-CN (f1-25)4P, β-CN 
(f3-28)4P, β-CN (f2-28)4P, β-CN (f2-29)4P, β-CN (f1-28)4P, β-CN (f1-29)4P, β-CN 
(f1-32)4P, αs1-CN(f61-79)5P, αs1-CN(f63-79)5P, αs2-CN(f7-21)4P were absent in the 
outer parts of the cheese form while they occurred in the inner one. In GP made 
using pasteurized milk, the different peptide profile was not observed owing to the 
phosphatase inactivation and lower proteolytic activity. Peptides as αs1-CN (f65-
74)3P, αs1-CN (f65-79)4P and β-CN (f16-25)3P were absent because CPP were not 
dephosphorylated by alkaline phosphatase (data not shown). Since indigenous ALP 
is fully inactivated in pasteurized milk, no gradient in free Ser depending on the 
unequal activity of the enzyme within the cheese form was observed and a diminutive 
amount of FAA was found in the core cheese form. In conclusion, the analysis of 
CPP of the inner and outer parts of the GP cheese form has provided some 
comprehensive information on the nature of the milk used in processing. 
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21. Conclusions 
 
 In conclusion, during the PhD work, a technique for selective enrichment of 
phosphorylated components has been developed starting from complex mixtures of 
proteins and peptides. The high selectivity technique of CPP enrichment based on 
hydroxyapatite (HA) chromatography was then transferred in semi-industrial scale for 
the formulation of a functional milk containing HA-CPP microgranules. HAS was 
synthesized by wet-chemical precipitation reactions from Ca(OH)2 and H3PO4 to 
reduce production costs and 3 different protein mixtures as casein, milk proteins and 
raw milk were used to recover tryptic CPP. It was thus possible to use several initial 
raw materials for preparing the new ingredient, according to the specific industrial 
needs.  
 Once CPP were bound to the resin, the complex HAS-CPP was finely ground 
and added to milk. The sensory characteristics of this new formulation were 
compatible for milk fortification. Hence, in this PhD work, a new drink enriched with 
functional components of high biotechnological interest as phosphopeptides has 
been created. CPP preparation was useful for the treatment of dental caries and 
vehiculing trace elements (copper, iron, selenium, etc).  
 The quality of the CPP preparation was also important. The evaluation of milk 
quality was conducted through the study of phosphoproteome of a mastitic milk 
sample. In this kind of milk, the developed analytical technique revealed new 
phosphorylated components in a wide range of dephosphorylation due to the 
increased phosphatase(s) activity associated to the high somatic cells and a number 
of plasmin-derived casein peptides. Dephosphorylation of proteins and CPP 
correlated well to high SCC having a negative impact on the functionality of the  
bioactive peptides.   
 Furthermore, the study of CPP dephosphorylation in the inner and outer parts 
of a 15-month-old cheese has allowed to find CPP as process markers. In a milk 
made by raw milk, a gradient of alkaline phosphatase and protease inactivation was 
associated to a thermal gradient between the core and outer parts of GP, while no 
gradient of inactivation was evident for a cheese made by pasteurized milk. In this 
direction, the analytical method is suitable to provide detailed information on the 
evaluation of the genuineness of liquid milk and cheese. The development of such a 
specific strategy opens up the possibility for further application in phosphoproteomics 
and structure-function studies.   
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Available online 20 December 2006Abstract—The general synthesis of a new class of non-natural diamino acids, 2-amino-3-[(2 0-aminoalkyl)seleno]propanoic acids, or
Se-(aminoalkyl)selenocysteines, is reported. Under the conditions devised, enantiopure N-Boc-protected b-L-iodoamines, which are
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Se–Se bond in commercial L-selenocystine. The Se-alkylation products were enantiomerically pure and the reaction is high yielding
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a (X = S), b (X = Se)Selenium is an essential micronutrient for animals and
humans: to date, its bio-availability seems to depend
upon the naturally occurring selenium-containing amino
acids selenocysteine (Sec) and selenomethionine,
although other selenoamino acids, such as Se-methyl-
selenocysteine, selenohomocysteine and selenocystathio-
nine, are also involved in selenoamino acid metabolic
pathways.1
In recent years, organoselenium chemistry has emerged
as an exceptional class of structures, due to its pivotal
role in the synthesis of a large number of biological com-
pounds and important therapeutic products ranging
from antiviral and anticancer agents to naturally occur-
ring food supplements.2
Simple organochalcogenide compounds have been
reported to display antioxidant activity in vitro and
in vivo. It has been suggested that the exploitation of
the redox activity of selenium, as in the case of tellu-
rium, could provide antioxidants of considerable
potency, which would be suitable tools in free radical
biology, as the scavengers of reactive oxidizing agents.30040-4039/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetlet.2006.12.096
Keywords: Organoselenium; Selenolanthionine; Selenocystine; b-Iodo-
amines; Diamino acids.
qChiral aminoalkyl cation equivalents, 2.
* Corresponding author. Tel.: +39 081 674117; fax: +39 081 674
102; e-mail: rocaputo@unina.it
Present address: Laboratorium fu¨r Organische Chemie, ETH Zu¨rich,
HCI Ho¨nggerberg, Wolfgang-Pauli-Strasse 10, CH-8093 Zu¨rich,
Switzerland.Exciting areas of research using chiral organoselenium
compounds also include catalytic asymmetric reactions
to provide enantiomerically enriched compounds, repre-
senting a new trend in this ﬁeld of organometallic
chemistry. In this context, chiral selenide- and diselenide-
containing ligands have been employed as useful cata-
lysts in various asymmetric transformations including
enantioselective addition of diethylzinc to aldehydes,4,5
the 1,4-addition of Grignard reagents to enones,6 and
palladium-catalyzed asymmetric allylic substitution.7Here we report the synthesis of new enantiopure non-
natural diamino acids (1) containing selenium. They
represent a new family of chalcogenide diamino acids
paralleling their sulfurated analogues that we have
recently reported.8 The interest of both classes of such
novel non-natural diamino acids depends essentially
upon their structural similarities with natural meso-lan-
thionine (2a), key-residue of lanthibiotic peptides and
meso-selenolanthionine (2b), respectively. Even more
interesting is their inclusion in peptides8 that performs
formal ‘bioconjugation’ processes,9,10 mimicking the
results of the alkylation, by proteinogenic a-amino acid
moieties, at the chalcogen atom of selenocysteines
(Sec), or cysteines (Cys) already present in peptide
NH-Boc
IPh
NH-Boc
SePhPh
3a 7
PhSeSePh
NaBH4
EtOH, THF
15 min, 94%
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iodoamines, obtained from aspartic and glutamic acids,
to alkylate a pre-existing cysteine in a solid-phase grow-
ing peptide was already reported.11
The synthesis of compounds 4a–c (Scheme 1) was
accomplished in a very simple, clean and high yielding
synthetic route starting from commercial L-selenocystine
and N(Boc)-b-L-iodoamines as Se-alkylation species.
The procedure reported for the synthesis of their sul-
fur-containing analogues8 could not be adapted, due
to the high tendency of L-selenocysteine to undergo oxi-
dation. Hence, L-selenocystine was reﬂuxed with NaBH4
in dry EtOH, under argon atmosphere, to produce
in situ (R)-2-amino-2-carboxyethaneselenolate anion.
The formation of the latter could be observed by the dis-
appearance of the initial intense yellow colour of seleno-
cystine ethanolic solution.12 The corresponding13,14
N(Boc)-b-L-iodoamine 3a–c (obtained from Phe, Pro
and Val, respectively) was then added to the solution
to alkylate the anion and after reﬂuxing the reaction
mixture for a few more minutes, the Boc mono-
protected selenodiamino acids 4a–c were observed as
sole products (TLC, LC–MS). Attempts to use cystine
under the same conditions to prepare sulfur analogues
of 4a–c were disappointing, due to the poorest reaction
yields.
Diamino acids 4a–c were not isolated as such,15 but were
converted into N,N-protected compounds, ready for
peptide coupling, bearing either a second Boc group
(5a–c) or orthogonal Boc/Fmoc (6a–c) protection
(Scheme 1).
We propose for any of these new chalcogen-containing
diamino acids an acronym to avoid cumbersome system-
atic names in the current laboratory practice and in
order to readily recognize their presence in peptide
sequences as well. The proposed acronym is composed
of ‘Se’ (from ‘Sec’) [as well as ‘Cy’ (from ‘Cys’) for the
terms containing the sulfur atom] and the italicized
‘one-letter code’ denoting the a-amino acid whose side
chain (R in formula 3 and others therefrom) is present
in it. Accordingly, the selenodiamino acids reported in
this Letter are shown in Table 1 with their acronyms
and the whole family should be referred to as ‘SeX ’ fam-HO2C
NH2
Se
CO2H
NH2
Se
R
NH-Boc
I
Se
R
NH-Boc
B
3
5
a: R = CH2C6H5           (Phe)
b: R = CH2CH2CH2N    (Pro)
c: R = CH(CH3)2          (Val)
NaBH4 in EtOH
reflux, 5 min
Scheme 1. Synthesis of N,N-protected SeX diamino acids from L-selenocystily [as well as ‘CyX’ family for the sulfur-containing
terms].
The stereochemical integrity of the ﬁnal products
was assessed by RP-HPLC, 1H and 13C NMR.
Selenium nucleophiles have been reported16 to react
with aziridines that act as chiral aminoalkyl cation
equivalents. In our experience, chiral b-iodoamines ap-
pear to be strongly competitive with aziridines: as an
illustrative example, we obtained almost quantitative
formation of (S)-tert-butyl 1-phenyl-3-(phenylselen-
yl)propan-2-ylcarbamate (7), in only a few minutes
using the protected b-iodoamine 3a, from N(Boc)-L-
phenylalanine, and benzeneselenolate anion generated
in situ from diphenyl diselenide and NaBH4 in reﬂuxing
EtOH. The same product had been reported17 to be
formed in 24 h, 72% yield, using the same benzeneselen-
olate anion and N(Boc)-aziridine from N(Boc)-L-
phenylalanine.In conclusion, these new, non-natural selenylated diami-
no acids can be obtained enantiopure, in good yields
and if required, in orthogonally protected forms ready
for insertion into peptide sequences. The synthesis is
very simple and the starting materials are generally inex-
pensive and easily accessible as well. All the mentioned
observations highlight the synthetic value of the enantio-
merically pure N(Boc)-b-iodoamines as aminoalkyl
cation equivalents.
It is also worth noting that the lysine-like conﬁguration
of our diamino acids, associated with a proteinogenic
side chain, prompts their exploitation as branching dia-
mino acids to build up chalcogen-containing peptide-
bond based new dendrimeric structures. Work is already
in progress in our lab to produce enzyme-mimicking
dendrimeric scaﬀolds including proteinogenic a-aminoCO2H
NH2
Se
R
NH-Boc
CO2H
NH-Boc
CO2H
NH-Fmoc
Se
R
NH-Boc
oc2O FmocOSu
4
6
ine and b-L-iodoamines.
Table 1. New N,N-protected SeX diamino acids
N(Boc)-b-L-Iodoamine SeX diamino acid Yielda (%) Mp (C) ½a25D ðCHCl3Þ
3a Boc–SeF(Boc)–OH (5a) 98 132–133 45.1
3a Fmoc–SeF(Boc)–OH (6a) 95 138–139 40.2
3b Boc–SeP(Boc)–OH (5b) 92 Foam 23.8
3b Fmoc–SeP(Boc)–OH (6b) 94 97–98 31.3
3c Boc–SeV(Boc)–OH (5c) 97 Foam 35.7
3c Fmoc–SeV(Boc)–OH (6c) 95 88–89 38.5
a Yield of diprotected selenodiamino acid, referred to the starting b-iodoamine.
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